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Current therapies against cancer have limited efficacy due to the lack of specificity, 
high toxicity and poor penetration in tumor tissue. The natural ability of bacteria to 
colonize and penetrate deep in tumors makes them potential vehicles for delivery of 
therapeutic molecules. Synthetic biology may allow the profound engineering of 
bacteria to improve tumor colonization, specificity, reduce bacterial toxicity, and make 
precision delivery of a payload of therapeutic molecules.  
In this PhD thesis, we have conducted research aimed to engineer Escherichia coli 
(E. coli ) bacteria using synthetic biology for precise adhesion and invasion of tumor 
cells, as well as for the delivery of protein payload in the cytoplasm of the tumor cell. In 
addition, we have investigated the influence of bacterial motility for specific tumor cell 
adhesion. 
First, we developed synthetic adhesins (SAs) that enable us to program the 
adhesion of E.coli bacteria to tumor cells expressing human epidermal growth factor 
receptor (EGFR), a surface receptor tyrosine kinase upregulated on many epithelial 
tumors such as bladder and colon carcinomas. SAs display a single domain antibody 
on the bacterial surface that specifically binds a target antigen expressed on the tumor 
cell surface (e.g. EGFR). We generated SAs binding human EGFR and showed their 
correct surface display expression in E. coli upon chromosomal integration under the 
control of a constitutive promoter. We demonstrate that these modified bacteria attach 
specifically to human bladder and colon epithelial tumor cell lines expressing EGFR.  
Next, we engineered the specific bacterial invasion of the targeted tumor cells by 
inserting, in the chromosome of bacteria expressing SAs, the gene encoding the 
invasin (Inv) protein from Yersinia pseudotuberculosis under the control of an inducible 
promoter. Further, we tested Inv expression in combination with the pore-forming 
protein Lysteriolysin O (LLO) from Listeria monocytogenes to elicit the release of a 
protein cargo in the cytoplasm of the targeted tumor cells.  
Synthetic adhesins against EGFR were also expressed in an E. coli strain 
producing minicells, non-live bacterial nanoparticles devoid of chromosomal DNA, that 
may represent an interesting alternative to the use of live bacteria for tumor targeting.  
We produced minicells simultaneously expressing SAs against EGFR on their surface 
and a cargo protein in their cytosol.  However, we found that adhesion of these 
minicells to EGFR-positive tumor cells was very poor compared with that of live 
bacteria expressing an identical SA. This result prompted us to investigate this 
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difference and lead us to discover the critical role of an active flagellar motility for 
efficient adhesion of E. coli bacteria to the target tumor cells.  
E. coli mutants lacking flagella or having a non-motile flagella are not able to bind 
tumor cells despite expression of SAs. This adhesion defect of non-motile bacteria is 
not compensated by bacterial movement in unidirectional flow or by centrifugation to 
force cell contact. We found that after an initial cell contact, an E. coli bacterium must 
establish simultaneously several adhesion points with the surface of the target cell in 
order to form a permanent adhesion event. Flagellar rotation in a single direction, either 
clock-wise or counter clock-wise, is sufficient to generate these local movements and 
to establish a permanent adhesion, which is characterized by the absence of bacterial 
motility. We found that the surface sensing pathway mediated by the lipoprotein NlpE 
and the flagellar "brake" protein YcgR, which binds to cyclic-di-GMP second 
messanger, are not needed for the permanent adhesion of bacteria to tumor cells.  
Lastly, we have extended our conclusions with SAs in E. coli to the adhesion of 
pathogenic bacteria to mammalian host cells during infection. We have demonstrated 
that flagella are also required for bacterial adhesion mediated by natural adhesins 





Las terapias actuales contra el cáncer poseen una eficacia limitada debido a la falta 
de especificidad, a su alta toxicidad y a su limitada capacidad de penetración en los 
tumores. La capacidad natural de las bacterias para colonizar y alcanzar áreas 
profundas del tumor las hace potenciales vehículos para la liberación de moléculas 
terapéuticas de manera eficiente. La biología sintética nos permite la modificación de 
las bacterias para mejorar la colonización de los tumores, aumentar la especificidad, 
reducir la toxicidad, y realizar una liberación precisa de moléculas terapéuticas en el 
interior del tumor.  
En esta tesis doctoral, la investigación ha sido dirigida a la modificación genética 
de la bacteria Escherichia coli (E. coli) utilizando biología sintética para conseguir una 
adhesión e invasión específica de las células tumorales, así como la liberación de una 
proteína "cargo" de interés en el citoplasma de la célula tumoral. Además hemos 
investigado la influencia de la motilidad bacteriana durante la adhesión específica a la 
célula tumoral.  
Primero, desarrollamos adhesinas sintéticas (SAs) que permiten la adhesión 
programada de E.coli a células tumorales que expresan el factor de crecimiento 
epidérmico (EGFR), un receptor tirosina-quinasa sobre-expresado en muchos tumores 
epiteliales humanos como por ejemplo los carcinomas de vejiga y colon. Las 
adhesinas sintéticas exponen en la superficie bacteriana un anticuerpo monodominio 
que se une específicamente a un antígeno expresado en la superficie de la célula 
tumoral (p.ej. EGFR). Hemos generamos SAs capaces de unir EGFR y se ha 
demostrado su correcta expresión en la superficie de E. coli tras su integración en el 
cromosoma bajo el control de un promotor constitutivo. Hemos demonstrado que las 
bacterias modificadas mostraban una adhesión específica a células tumorales 
humanas de vejiga y colon que expresan EGFR. 
A continuación se generó la invasión específica de estas células tumorales 
insertando en el cromosoma de la cepa modificada con SAs, el gen que condifica a la 
proteína invasina (Inv) de Yersinia pseudotuberculosis bajo el control de un promotor 
inducible. Además, se testó la expresión de la invasina en combinación con la proteína 
formadora de poros Listeriolisina O (LLO) de Listeria monocytogenes para producir la 
liberación de una proteína "cargo" en el citoplasma de las células tumorales.  
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Las adhesinas sintéticas contra EGFR también fueron expresadas en una cepa de 
E. coli productora de minicélulas, partículas bacterianas no vivas carentes de 
cromosoma, que pueden representar una alternativa interesante al uso de bacterias 
vivas frente a tumores.  Hemos generado minicélulas expresando SAs que reconocen 
EGFR y una proteína "cargo" en el citoplasma. Sin embargo, en nivel de adhesión de 
estas minicélulas a las células tumorales que expresan EGFR fue muy bajo en 
comparación con las bacterias vivas expresando las mismas SAs. Este resultado nos 
condujo a estudiar las diferencias entre bacterias y minicélulas que podían explicar su 
distinto nivel de adhesión y descrubrimos la importancia de la motilidad bacteriana 
para una adhesión efectiva de E. coli a la célula tumoral diana.  
Los mutantes de E. coli sin flagelo, o que expresan un flagelo no motil, no se unían 
a las células tumorales a pesar de expresar las SAs. Esta baja adhesión de las 
bacterias no motiles no se podía compensar mediante el movimiento de las bacterias 
en un flujo unidireccional o por centrifugación para forzar el contacto con la célula. 
Descubrimos que tras un contacto inicial, E. coli debe establecer simultáneamente 
varios puntos de adhesión con la superficie de la célula diana para crear una adhesión 
permanente.  La rotación flagelar en una sola dirección, a favor de las agujas del reloj 
o en contra de las agujas del reloj, es suficiente para generar estos movimientos 
locales y para establecer la adhesión permanente de la bacteria, que se caracteriza 
por la ausencia de movimiento de la bacteria. También observamos que ni la ruta para 
sensar superficies mediada por la lipoproteína NlpE, ni la proteína “freno” YcgR, que 
une el dinucleotido cíclico de guanosina difosfato (cyclic-di-GMP), son requeridas para 
la adhesión permanente de la bacteria a las células tumorales.  
Finalmente, hemos extendido nuestras conclusiones obtenidas con E. coli 
expresando SAs pueden aplicarse a la adhesión de bacterias patógenas a las células 
del huesped mamífero. Hemos demostrado que el flagelo es necesario para la 
adhesión mediada por adhesinas naturales presentes en E. coli uropatógenas y en 





-Characterization of the binding affinity and epitope recognition of anti-EGFR 
nanobodies selected by E. coli display for their application in synthetic adhesins. 
 
-Generation of engineered E. coli strains constitutively expressing synthetic 
adhesins anti-EGFR for targeting bladder and colon epithelial tumor cells. 
 
-Engineer E. coli strains targeting EGFR-positive epithelial tumor cells with invasive 
capabilities for the specific release of a protein cargo in the tumor cell.  
 
- Evaluate the potential of synthetic adhesins anti-EGFR expressed in non-live E. 
coli-derived minicells for targeting epithelial tumor cells and release of a protein cargo. 
 






1. The use of bacteria fighting cancer.  
Bacteria were first explored as an alternative cancer treatment nearly 150 years 
ago. The first doctor using on purpose bacteria as an anti-tumor agent probably was 
the German physician W. Bush in 1868, inducing a bacterial infection in a patient 
presenting sarcoma (Pawelek et al., 2003). Almost 30 years later the American 
physician William Coley was the first to experiment with bacteria treatments for cancer 
by injecting his patients presenting sarcoma with various combinations of live and heat-
killed bacteria Streptococcus pyogenes. Eventually he developed a mixture called 
Coley´s toxin that caused regression of the majority of tumors, sometimes even the 
entirely elimination of them (Coley, 1891; Pawelek et al., 2003). However, the lack of 
knowledge about the mechanism of action of bacteria, together with the inability to 
control infection in this pre-antibiotic era, as well as the advent of radiotherapy and 
chemotherapy, relegate this type of treatment (Malmgren and Flanigan, 1955).  
Since then, several genera of bacteria have been shown to colonize solid tumors, 
all of them anaerobic or facultative anaerobic bacteria including Clostridium (Nuyts et 
al., 2002; Theys et al., 2001), Listeria (Quispe-Tintaya et al., 2013; Zhou et al., 2018), 
Salmonella (Forbes et al., 2003; Pawelek et al., 1997; Ryan et al., 2009), 
Bifidobacterium (Fujimori et al., 2002; Yazawa et al., 2001) and Escherichia (Yu et al., 
2004; Zhang et al., 2012). An advantage of facultative anaerobes, such as Salmonella 
and E. coli, is that they are highly motile and colonize oxygenated as well as hypoxic 
and necrotic tumor regions. Nowadays, these observations and the development of 
synthetic biology have triggered a re-emergence of the use of bacteria as anti-tumor 
vectors. 
 
1.1 The natural ability of bacteria for colonizing tumors.  
The fast growth of tumors require the formation of new blood vessels that provide 
nutrients and oxygen to the dividing tumor cells. However, tumor neovasculature is 
disorganized and fenestrated, with areas having poor vascularization, resulting in 
acidity and nutrient deprivation as well as areas with reduced oxygen concentration 
inside the tumor. This poor vascularization of solid tumors also makes certain areas 
less accessible to chemotherapeutic agents and the lack of oxygen makes the tumor 
cells more resistant to ionizing radiations (Ha et al., 2012). Bacterial therapies have 
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gained interest to access these therapeutically-resistant tumor areas (St Jean et al., 
2008). 
Bacteria released in the blood stream can reach the tumor thanks to its leaky 
neovasculature and proliferate in the hypoxic tumor core due to the absence of 
immune system cells. It has also been described a specific chemotaxis of bacteria 
toward necrotic tumor regions, which are rich in amino acids and other complex 
metabolites (Lyssiotis and Kimmelman, 2017). This exceptional tumor 
microenvironment explain the preferential growth of bacteria in tumors and not in 
healthy tissues (St Jean et al., 2008). 
Another important characteristic of bacteria for colonizing tumors is their ability of 
active movement. Motile bacteria can reach the non-vascularize tumor areas thanks to 
its active motility, being able to access and proliferate in these regions in contrast to 
the chemotherapeutic drugs, viruses, liposomes and antibodies, which all rely on 
passive diffusion (Raman et al., 2019; St Jean et al., 2008).  
Once in the tumor area, bacteria may cause an anti-tumor effect by various 
mechanisms, including direct cytotoxicity against cancer cells, competition for limited 
nutrients, and activation of the immune system (Kaimala et al., 2018).  
Bacteria have a large number of endogenous structures, called pathogen-
associated molecular patterns (PAMPs), such as flagellin, fimbriae, lipopolysaccharide 
(LPS), peptidoglycan (PG), and lipotechoic acids, which are recognized by specific 
receptors present in immune cells (e.g. Toll-like receptors - TLRs- and NOD-like 
receptors -NLRs) that trigger signalling cascades activating the immune response 
(Brubaker et al., 2015; Kawasaki and Kawai, 2014). The stimulation of the immune 
system triggered by bacteria may reverse the immunosuppression presented in late-
stage tumors that causes cancer dissemination (Middlebrook and Dorland, 1984).  
Metastatic cancers and multidrug-resistant tumors are also susceptible of being 
treated with a bacterial therapy making microbial therapies able to provide solution to 
many clinical need not reachable for the traditional treatments (Forbes et al., 2018).   
The most clear example of immunotherapy using bacteria is the current treatment 
for superficial bladder cancer with Bacillus of Calmette Guerin (BCG), an attenuated 
strain of Mycobacterium bovis (Gandhi et al., 2013) which causes a non-specific 
stimulation of the immune response against the tumor after instillation of BCG bacteria 
in the urinary bladder of patient (Kamat et al., 2014). 
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1.2 Bacterial motility and it role in tumor colonization. 
Motility is an important characteristic of bacteria for colonizing tumor (Toley and 
Forbes, 2012). Bacteria can reach the non-vascularize tumor areas thanks to its 
motility and proliferate in these regions where traditional antitumor-drugs, viruses, 
liposomes and antibodies cannot penetrate because they rely on passive diffusion and 
not in active transport (Raman et al., 2019; St Jean et al., 2008).  
The principal organelle for bacterial motility in facultative anaerobes such E. coli or 
Salmonella is flagella (Haiko and Westerlund-Wikstrom, 2013). Flagellar motor 
responds to the chemoreceptor system to redirect swimming toward beneficial 
environments (Chaban et al., 2015). The chemotaxis system regulates the swimming 
behavior of the bacteria by controlling the rotational direction of their flagellar motors 
(Fukuoka et al., 2012).  Extracellular stimuli sensed by chemoreceptors are transduced 
to an intracellular signal molecule, phosphorylated CheY (CheY-P), which switches the 
rotational direction of the flagellar motors from counterclockwise (CCW) where bacteria 
swims in linear movement, to clockwise (CW) where bacteria swims in tumble mode 
(Fukuoka et al., 2012). 
It has been described that quiescent tumor cells in the core of solid tumors acts as 
attractants for Salmonella and the chemotaxis is essential for its penetration and 
accumulation in tumors (Kasinskas and Forbes, 2007). Non-motile Salmonella mutants 
accumulate in solid tumors 26 times less than the wild type strain, showing the 
essentiality of flagella in tumor colonization (Raman et al., 2019).  
Flagellar synthesis is highly regulated process in E. coli and related species 
(Fitzgerald et al., 2014) its expression is regulated by the flhDC protein complex, which 
control the expression of at least 14 operons encoding more than 40 genes involved in 
the flagella structure (Liu and Matsumura, 1994). Overexpression of FlhDC increases 
intracellular accumulation and tumor colonization 2.5 to 5 times more than wild type 
Salmonella (Raman et al., 2019). 
The flagellum is made of three major parts: the basal body, the hook and the 
filament. The basal body works as a reversible rotary motor, and the filament, typically 
10–15µm long, serves as a helical propeller. The hook is a universal joint that connects 
the motor with the filament to transmit torque regardless of the orientation of the 
filament propeller (Berg, 2003; Chen et al., 2011; Hosu et al., 2016; Macnab, 1999). 
The flagellar motor is powered by the electrochemical potential difference of hydrogen 
or sodium ions across the cytoplasmic membrane (Berg, 2003; Minamino et al., 2008). 
In Salmonella and E. coli, motor torque is generated by rotor–stator interactions 
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coupled with proton translocation through the channel formed within the stator. The 
Mot complex is composed of two cytoplasmic membrane proteins, MotA and MotB, 
which form a MotA4/MotB2 hetero-hexameric complex (Terashima et al., 2008). 
Figure 1. A scale drawing of the base of the E. coli flagellum embedded in three layers of the 
cell Wall (Hosu et al., 2016).  
 
 
2. Engineered bacteria as agents to fight cancer 
2.1.1 2.1. Reducing bacterial pathogenicity in tumor therapies. 
Bacteria can be easily genetically modified to reduce the pathogenicity and 
increase the anti-cancer effects which comprises another positive point to develop a 
anti-cancer therapy using those microbes. 
An important issue to consider before develop an antitumor-bacterial therapy is the 
strain of bacteria used. As mentioned above, different bacterial genera have the 
potential to be used for cancer therapy but all of them have their own unique properties 
in tumor colonization, their ability to invade tumor tissue and the interaction with the 
immune system (Chien et al., 2017). Reducing the pathogenicity of bacteria is maybe 
one of the most important issues to overcome. Bacteria like Salmonella or Clostridium 
are very immunogenic, which is appropriate for developing an immunotherapy 
approach but also may cause a septic shock in case of systemic infection. Salmonella 
strains have received more attention so far as anticancer agents because of the large 
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understanding of their pathogenicity, physiology and genetics, which drives to defined 
attenuation strategies. 
The most used bacteria are the genetically attenuated VPN20009 and the A1-R 
strains of S. typhimurium . The strain termed VNP20009 from Salmonella posses 
mutations in the genes purI and msbB (lpxM) involved in the synthesis of purines and 
LPS respectively. Due to the purines auxotrophy the strain grow preferentially inside 
the tumors (Pawelek et al., 1997) and due to deletion of msbB the mutant produce a 
penta-acylated lipid A of LPS that is weakly recognized by the TLR4 (Wang et al., 
2016). VNP 20009 strain had being widely used for tumor targeting to deliver 
anticancer agents and carrying shRNA- expressing plasmids (Forbes et al., 2018). 
The A1-R strain selectively grows in tumor xenografts and was developed by 
treating S. typhimurium with the mutagenic agent nitrosoguanidine (NTG) to induce 
auxotrophic mutants that were later selected by ability to grow in successive tumor 
xenografts (Zhao et al., 2005). S. typhimurium strain A1 was recovered from this 
selection and identified as a leucine and arginine auxotroph. Presumably, the 
auxotrophic strains receive sufficient amounts of these amino acids from the tumor 
environment but do not persist in the normal tissue environment (Wang et al., 2016). 
VNP20009 has also been used in clinical trials with modest results (Cunningham and 
Nemunaitis, 2001; Dramsi and Cossart, 2002). Clinical trials using systemic 
administration of Salmonella for human cancer therapy revealed that the highest 
bacterial dose that was tolerated was still insufficient for an effective colonization 
(Kocijancic et al., 2016; Kramer et al., 2018). 
 E. coli is extensively used as model host for synthetic biology studies and has the 
advantage of naturally having non- pathogenic strains that can be used without further 
attenuation because of that is the second most widely used microorganism in cancer 
therapy (Chien et al., 2017). There are also E. coli strains accepted as probiotics like E. 
coli Nissle 1917 that have been shown to colonize solid tumors (Danino et al., 2015; 
Loessner et al., 2009; Stritzker et al., 2007). E. coli Nissle had been modified for tumor 
local delivery of chemotherapeutics (eg. Doxorubycin) (Xie et al., 2017),  anti-
angiogenic and pro-apoptotic agents like p53 or Tum-5 (He et al., 2019), bacterial 
toxins (Li et al., 2019), or other molecules such the pro-apoptotic fusion protein TAT-
apoptin (Zhou et al., 2011).  
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2.2 Delivery of anti-tumor molecules by bacteria. 
To induce tumor regression and elimination, bacteria can be engineered to express 
and release cytotoxic proteins such as bacterial toxins (Bishr et al., 2014; Ha et al., 
2012; Jiang et al., 2010), pro-drug converting enzymes (Lehouritis et al., 2013), 
immunoregulatory proteins (Loeffler et al., 2007) and apoptosis-inducing factors (Ganai 
et al., 2009; Loeffler et al., 2009) that may induce tumor regression and elimination 
Figure 2.  
In the field of the bacterial toxins the most commonly used are the pore-forming 
cytolysins, such as hemolysin E (HlyE / ClyA) from E. coli (Jiang et al., 2010; Ryan et 
al., 2009) and alpha-hemolysin (SAH) from Sthaphylococcus aureus (Bishr et al., 2014; 
St Jean et al., 2014). Theses proteins are secreted in monomers and polymerize 
forming pores able to be incorporate into the plasma membrane of mammalian cells 
(Gouaux, 1998; Henrichsen, 1983).  Another interesting strategy used has been the 
delivery of Flagellin B from Vibrio vulnificus that leads to recruitment of macrophages 
and tumor regression in the tumor area (Zheng et al., 2017). 
Bacteria also can be equipped with genes encoding for prodrugs converting 
enzimes such herpes simplex virus thymidine kinase (TK) or E. coli cytosine 
deaminase (Lehouritis et al., 2013) able to convert a nontoxic compound (i.e. 
ganciclovir, 5-Fluorocytosine) in a toxic compound or drug  (i.e. ganciclovir 
monophosphate, 5 Fluorouracil) that is going to affect the cells expressing these 
enzymes or in their vicinity within the tumor area. 
Also apoptosis inducing factors and cytotoxic cytokines have been explored such 
as FAS ligand (FASL), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
and Tumor necrosis factor alpha (TNFα). These molecules are able to induce 
apoptosis and are more toxic for tumor cells than for healthy cells (Ganai et al., 2009; 
Loeffler et al., 2009; Murphy et al., 2017). Local release of these cytotoxic cytokines 
alleviates their toxicity after systemic administration. 
Other cytokines instead of triggering directly tumor cell apoptosis, they are able to 
activate the host immune system to clear the tumors. IL-2 has been the most 
extensively used for activating the cytolytic function of the natural killer (NK) cells and 
promoting lymphocytes activation (Barbe et al., 2005; Ha et al., 2012).  IL-18 has also 
been investigated with this aim (Loeffler et al., 2008). 
Genetic transfer to tumor cells of genes encoding for cytotoxic agents (Fu et al., 
2008) antiangiogenic factors like endostatin and thrombosponding 1 which kill tumors 
by preventing the formation of new blood vessels (Liang et al., 2018) or cytokines 
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genes like IL-12, granulocyte/macrophage colony stimulating factor (GM-CSF) (Yuhua 
et al., 2001) has been also addresses with tumor targeting bacteria. 
Gene silencing has also been achieved by transferring plasmids encoding small 
hairping RNA (shRNA) from Salmonella into cancer cells (Tian et al., 2012). 
Gene-specific shRNA are processed into small interfering RNA (siRNA) that induce 
degradation of the target mRNA, targeting the factor signal transducer and activator of 
transcription 3 (Stat3) induced remarkably delayed and reduce hepatocellular 
carcinoma in mice (Tian et al., 2012). 
 
Figure 2. Scheme showing some approaches to improve bacteria as agents in cancer 
therapies. Bacterial accumulation inside tumors is favored by the leaky vasculature of blood 
vessels found in tumors (red marks in the blood vessel) The scheme includes expression of 
reporter genes to follow infection in real time, generally by light emission (yellow wavy lines), 
localized secretion of bacterial toxins (green dots), bacterial-directed enzyme prodrug therapy 
(BDEPT) that allows site-specific conversion of prodrugs (yellow molecule) into drugs (red  
molecule), localized secretion of cytokines (orange dots) to stimulate immune cells (grey cells), 
intracellular secretion of pro-apoptotic molecules (blue stars) and release of expression vectors 
(purple circles) coding for different genes or shRNAs. 
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2.3 Bacterial delivery of therapeutic macromolecules into tumor 
cells. 
The delivery of therapeutic molecules requires release of the macromolecule from 
the bacteria after colonization of the tumor. Various bacteria delivery systems had been 
developed for this purpose. 
As mentioned above, a simple approach is the release of pore-forming cytolysins 
(Bishr et al., 2014; Jiang et al., 2010; Ryan et al., 2009; St Jean et al., 2014). These 
molecules are natively expressed and secreted by bacteria and able to induce 
apoptosis in mammalian cells (Stanley et al., 1996; Swofford et al., 2014). 
Unfortunately they represent an special situation, as most macromolecules are not able 
to pass through bacterial membranes for their release. Fusion with an N-terminal signal 
peptide to enable bacterial secretion of foreign polypeptides represents a different 
alternative (Mergulhão et al., 2005; Ni and Chen, 2009), albeit this approach is limited 
to a small fraction of proteins that are compatible with transport across the bacterial 
membranes. A broader spectrum of macromolecules can be reach by induction of 
bacterial lysis, which releases all the bacterial protein content in the tumor environment 
(Din et al., 2016). For instance, the mitochondria target domain (MTD) of Noxa, 
implicated in the mitochondrial apoptotic pathway, was delivered fused to a cell 
penetrated peptide by an attenuated Salmonella strain lysed by the induction of a 
bacteriophage lysin (Bereswill et al., 2014). Also, syncronized cycles of bacterial lysis, 
by the induction of bacteriophage lysin under the control of quorum sensing promoters 
(see later), have been used to release HlyE (Din et al., 2016). 
Bacteria can also be modified to deliver nucleid acids such shRNAs or DNA 
vectors. To achieve this, E. coli was transformed with a plasmid encoding the invasin 
(inv) from Yersinia pseudotuberculosis and and listeriolysin O (LLO; hlyA gene) from 
Listeria monocytogenes (Fajac et al., 2004; Grillot-Courvalin et al., 1998). Invasin 
triggers internalization of the bacteria into a phagosome inside the tumoral cell and 
LLO appears to facilitate the release of the nucleic acids into the tumor cell cytoplasm 
(Critchley et al., 2004; Xiang et al., 2006). 
In addition, pathogenic bacteria often encodes protein delivery systems that 
function during infection (Costa et al., 2015) and which may have the potential to be 
engineered for extracellular and/or intracellular release of therapeutic proteins. Among 
them, research in our laboratory has used type I secretion systems (T1SS) for 
extracellular release of antibody fragments (Blanco-Toribio et al., 2010); (Van Impe et 
al., 2013) and type III secretion systems (T3SS) for intracellular delivery of antibody 
fragments into the cytoplasm of mammalian tumor cells (Ruano-Gallego et al., 2015). 
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Interestingly, our group has generated a non-pathogenic E. coli K-12 strain, called 
SIEC for Synthetic Injector E. coli, able to assemble functional filamentous injectisomes 
of the T3SS from enterophatogenic E. coli (EPEC) for protein delivery into mammalian 
cells (Ruano-Gallego et al., 2015). However, these systems have not been yet used for 
protein delivery in tumors in vivo. 
 
2.4 Controlling the expression in vivo of therapeutic proteins in 
bacteria. 
Gene expression add an important control point to bacterial therapies managing the 
time and location of the drug production. The incorporation of specific promoters 
sequences uptream of genes encoding for anti-cancer molecules enables the control of 
the transcription by external signals and minimize toxicity. Some gene products require 
tighter control due to their cytotoxic effects while non-toxic proteins (e.g. enzymes, 
antigen) may not need such level of control (Forbes, 2010). 
Bacterial promoters used in vivo for controlling therapeutic proteins can be divided 
in two main cathegories, namely those responding to external inductors and those 
responding to local enviromental signals (Chien et al., 2017). In E. coli and Salmonella 
the promoters that are more commonly used in vivo with external non-toxic inductors 
are the tetracycline promoter (tetR-PtetA) (Bertram and Hillen, 2008), which can be 
induced with anhydrotetracycline (aTc), a non-antibiotic tetracycline analog, and the 
arabinose promoter (araC-PBAD) (Hong et al., 2014), which is induced with L-
arabinose, a pentose commongly found in plant polysaccharides and that is 
metabolized by many bacteria but not by human cells (Jiang et al., 2010; Loessner et 
al., 2007).  An interesting alternative is the salicylate promoter cascade system which 
amplifies gene expression and is induced with salicylate and its derivatives (e.g. acetyl-
salicylate) (Cebolla et al., 2002). 
Promoters responding to a physical inducer, rather than a molecular inducer, have 
also been used in vivo. For instance, γ-irradiation promotes DNA damage, which then 
causes the degradation of LexA repressor, inducing SOS repair system (Ganai et al., 
2009). Thus, use of a SOS-responsive promoter (e.g. recA) can trigger expression of 
the therapeutic protein of interest upon γ-irradiation (Murphy et al., 2017).  Irradiation 
has a major advantage over the molecular triggers because γ-irradiation can directly 
penetrate tumor tissue and is not restricted by diffusion limitations (Chien et al., 2017). 
On other hand, local enviromental signals can be detected by bacteria to induce the 
expression of the protein of interest. For instance, since hypoxia is a common condition 
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present in the core of solid tumors, endogenous E. coli promoters controlled by the 
oxygen-responsive transcriptional regulator FNR can be used for the expression of a 
therapeutic molecule (Mengesha et al., 2006; Ryan et al., 2009). Also a a synthetic 
promoter has been constructed for for detect hypoxia in Deyneko et al. by incorporating 
hypoxia sensing elements (Deyneko et al., 2016). 
Interestingly, some promoters activated preferentially within tumors have been 
identified in Salmonella typhimurium carrying promoter libraries driving expression of 
GFP (Arrach et al., 2008; Leschner et al., 2012). 
In addition, since bacteria grow in high numbers within the tumor tissue and not in 
healthy tissue, the quorum sensing molecules accumulated in the tumor environment 
have been used to specifically induce the expression of therapeutic proteins in solid 
tumors (Din et al., 2016; Swofford et al., 2015). 
 
2.5 Bacterial minicells and tumor therapy. 
An interesting alternative to live bacteria could be the use of non-living bacterial 
minicells (MacDiarmid and Brahmbhatt, 2011). Minicells are small spherical bacteria-
derived nanoparticles (ca. 400 nm in diameter) that lack chromosomal DNA and 
therefore are not able to proliferate. Minicells were originally reported in E. coli more 
than 50 years ago (Adler et al., 1967) but many Gram-positive and Gram-negative 
bacteria are known to generate minicells by deletion of their minCD genes, which are 
required for of the proper placement of the cell division FtsZ ring (Romberg and Levin, 
2003). Subcellullar location of the Z ring is regulated by the Min proteins and a 
negative spatial regulator of Z-rings called “nucleoid occlusion” which disable the Z-ring 
assembly in the space occupied by the bacterial chromosome (Rowlett and Margolin, 
2015). In the ∆minCD mutants the Z-ring can assemble near the cell poles, resulting in 
an asymmetrical bacterial division producing a large cell keeping the bacterial 
chromosomes and a smaller minicell with exactly the same composition of the 
replicative bacterial cell except for the lack of the chromosomal DNA. Hence, minicells 
contain cellular membranes, peptidoglycan, ribosomes, RNAs, proteins and plasmids, 
and they can continue cell processes like ATP synthesis, replication and transcription 
of plasmid DNA and translation of mRNA (Farley et al., 2016). 
The use of minicells as nanovehicles for the delivery of chemotherapeutics (e.g. 
Doxorubicin) and siRNAs to tumors was originally reported using Salmonella minicells 
(MacDiarmid et al., 2009; MacDiarmid et al., 2007). The accumulation of minicells in 
solid tumors is only partially due to their small size and was enhanced with bi-specific 
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antibodies that recognizes the LPS in the minicell surface and a surface receptor on 
the tumor cell, such as the growth factor receptors EGFR and HER2. After their 
systemic administration, minicells loaded in vitro with various chemotherapeutics and 
siRNA were shown to accumulate in solid tumors and release their toxic payload by a 
non-completely understood mechanism, which may require lysis of minicells and/or 
their internalization by tumor cells (reviewed in MacDiarmid, 2011 #284). More 
recently, different studies have investigated and expanded the use of Salmonella and 
E. coli minicells against various human tumors (Zhang, 2018; Alfaleh 2017; McDiarmid 
2016). 
Figure 3 Electron micrograph showing an E. coli cell producing a minicell (Magnification 
X66000). Image taken from (Adler et al., 1967). 
 
3. E. coli as a suitable host for synthetic biology engineering and 
tumor therapies. 
Synthetic biology (the deliberate redesign and construction of novel biological parts, 
devices and systems to perform new functions for useful purposes) provides new 
opportunities to improve bacterial tumor therapies, designing the whole bacteria, 
eliminating unwanted genes in the chassis by genome manipulation, and incorporating 
gene circuits responding to external signals that could control the expression of 
therapeutic proteins and elicit bacterial biocontainment (Cameron et al., 2014; Chien et 
32MICROBIOLOGY: .-ADLER ET AL.
FIG. 1.-Thin-section electron micrograph showing a cell producing a minicell. X66,000.
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al., 2017; Lee et al., 2018). Given its genetic amenability, E. coli is frequently used as a 
model microorganism in synthetic biology developments. Interestingly, many E. coli 
strains fullfill the properties found in Salmonella for good tumor colonization, including 
its facultative anaerobic growth, its flagellated motility and genetic amenability, plus 
having the extra benefit of being non-pathogenic and non-invasive. Different studies 
have demonstrated that non-pathogenic commensal E. coli strains, like the laboratory 
K-12 strain MG1655 and the probiotic strains (e.g. Nissle 1917) are able to colonize 
solid tumors grafted in both immunodeficient (athymic Nude) and immunocompetent 
mouse strains (Balb/c, C57BL/6) (Brader et al., 2008; Kocijancic et al., 2016; Stritzker 
et al., 2007; Weibel et al., 2008). These studies administered a dose of these natural E. 
coli strains of ca. 5x106 - 1x107 CFU administered intravenously (i.v.) per animal to 
obtain efficient tumor colonization ( ≥ 90%). One hour after systemic administration, 
approximately 1 x 103 CFU reached the tumor, followed by an exponential growth, E. 
coli reached ca. ~1x108 CFU/g of tumor in 48 hours and persisted in both 
immunodeficient and immunocompetent mice over two weeks (Weibel et al., 2008). 
Most E. coli bacteria in tumors were located in the area between the necrotic and the 
proliferating tumor tissue. Importantly, E. coli counts remain low in healthy organs, 
such as livers and spleens (<1x102 CFU/g), which contrasts with the reported 
proliferation in these organs of Salmonella strains. 
 
3.1 Improving E. coli tumor targeting and colonization with 
programmed bacterial adhesion. 
Research in the host laboratory of this PhD thesis is currently aimed to the 
development of synthetic bacteria based on the modification of E. coli chassis from 
non-pathogenic strains (e.g. K-12, Nissle) with various "genetic modules" that can 
provide new functional capacities to the resulting bacteria useful for biomedical 
applications, including bacterial cancer therapies (Pinero-Lambea et al., 2015b). A 
genetic module that was developed is inteded to program the adhesion properties of 
the synthetic bacterium, allowing attachment to specific target surfaces or cells (Pinero-
Lambea et al., 2015a). This adhesion module is based on the expression of 
recombinant protein fusions on the surface of bacteria named as "synthetic adhesins" 
(SAs). SAs comprises the N-terminal fragment of intimin enterohemorrhagic E. coli 
(EHEC), called Neae (Bodelon et al., 2009), which anchors the polypeptide to the 
bacterial outer membrane with a ß-barrel (Fairman et al., 2012), fused to a single-
domain antibody domain, known as nanobody (Nb) review (Muyldermans, 2013), which 
is displayed on the bacterial surface providing the binding specificity (Pinero-Lambea et 
al., 2015a). A Nb is recombinant antibody fragment encoded by a single variable gene 
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segment (VHH) from heavy chain-only antibodies (HCAbs) that are naturally found in 
camelids (e.tg. dromedaries, llamas) (Muyldermans, 2013). Despite their small size 
(ca. 15 kDa) and simpler structure than conventional antibodies with heavy and light 
chains (ca. 150 kDa for IgGs), Nbs able to bind their cognate antigen with high affinity 
and specificity. In addition, Nbs have very interesting characteristics, such as good 
expression levels, strict monomeric behaviour, high stability to denaturants and 
proteases, reversible folding, binding of epitopes distinct from those recognized by 
conventional antibodies, and show high sequence similarity to human VH3 sequences 
(Harmsen and De Haard, 2007; Muyldermans, 2013). These properties have made 
Nbs attractive for various applications, including cancer diagnostics and therapy 
(Arezumand et al., 2017; Pleiner et al., 2015; Steeland et al., 2016). 
The expression of SA gene fusions is driven by a strong constitutive promoter (PN25) 
(Brunner and Bujard, 1987) and this genetic module was inserted in the chromosome 
of E. coli replacing the flu gene (Piñero-Lambea et al., 2015) which encodes the 
Antigen 43 autotransporter (van der Woude and Henderson, 2008). SAs were 
integrated in E. coli K-12 MG1655 strain lacking type 1 fimbriae (DfimA-H), which is a 
natural adhesin binding human urothelium (Bower et al., 2005), and carrying a 
bioluminiscence reporter (luxCDABE operon) replacing another major conserved E. 
coli fimbrial adhesin (mat) (Garnett et al., 2012). A marker-less gene 
deletion/integration strategy was employed, which leaves no antibiotic resitance genes 
nor recombination sequences ("scars") in the chromosome of the engineered strain 
(Posfai et al., 1999). The first SAs generated as a proof-of concept used Nb domains 
binding model antigens, such as GFP or the translocated intimin receptor (Tir) of 
enterohemorraghic E. coli (EHEC). It was demonstrated that engineered E. coli 
bacteria carrying SAs attached quickly (< 10 minutes) and in high numbers to HeLa 
tumor cells stably transfected to express on their surface these model antigens (e.g. 
GFP or TirM fused to a transmembrane domain of platelet-derived growth factor 
receptor, PDGFR) (Pinero-Lambea et al., 2015a). Importantly, using subcutaneous 
tumor xenograft mouse models in athymic Nude mice, it was also shown that the 
engineered E. coli bacteria expressing the SA against GFP were able to colonize more 
efficiently solid tumors of HeLa cells expressing GFP on their surface. The engineered 
strain colonized >90% of HeLa-GFP tumors in mice using two-order of magnitud lower 
dose of systemic bacteria (105 CFU/mouse) than control strains, which requiered ca. 
107 CFU/mouse to achieve similar colonization levels (Pinero-Lambea et al., 2015a). 
The engineered E. coli strain proliferated in tumors reaching ca. 108 CFU/gr of tumor 4-
days after its systemic administration, similar to what was previously reported with wild-
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type E. coli K-12 MG1655 (Weibel et al., 2008). In addition, the engineered strains 
were cleared faster than E. coli K-12 MG1655 from non-target healthy organs (e.g. liver 
and spleen) probably due to the deletion of natural adhesins (i.e. type 1 fimbriae, 
Antigen 43 and Mat fimbriae). 
Hence, these results with model antigens clearly indicated that SAs allow to 
program the adhesion capacities of bacteria to target cells, which help to reduce the 
bacterial dose required to colonize solid tumors expressing the target antigen.  
Lowering the bacterial dose administered will help to minimize major side effects 
caused by infection, as those observed in clinical trials with Salmonella strains 
(Nemunaitis et al., 2003; Toso et al., 2002). 
 
Figure 4. Scheme of the primary structure of SAs (left) showing the N-terminal domain of 
Intimin (Neae), comprising the signal peptide (SP), LysM, β-domain and D0 Ig-like domain, 
fused to a variable Ig domain from heavy-chain-only antibodies (VHH). The E-tag and myc-tag 
epitopes flanking the VHH domain are also indicated. Structural model of a SA fusion protein 
(right) in the bacterial outer membrane (OM) showing the LysM domain in the periplasm (yellow 
sphere), the β-barrel of Intimin embedded in the OM, and the D0 and VHH Ig-domains exposed 
to the extracellular milieu 
 
3.2 Targeting actual tumor-associated cell surface antigens. 
An important limitation of the poof-of-concept experiments with SAs is that the 
targeted proteins (i.e. GFP, Tir) were not actual antigens expressed by tumor cells. 
Therefore, the model used HeLa tumor cells stably transfected to express these 
antigens on the cell surface (Pinero-Lambea et al., 2015a). Transfection produced very 
high expression levels of the model antigen on the tumor cell surface, which are not so 
common in actual tumor-associated cell surface antigens in vivo.  At this point, the next 
step was to move the SAs to target proteins differentially expressed on tumor cell 
surface in comparison with the healthy tissue. Expression of cell surface proteins in 
cancer cell is frequently dysregulated, leading to the production of tumor-associated 
cell surface antigens that often correlate with tumor progression and metastasis, being 
an important factor to the prognosis an selection of therapy. 
	 33	
In many different cancer types, especially those of epidermal origin, the ErbB 
pathway becomes hyperactivated by different mechanisms, including overproduction of 
ligands, overproduction of receptors or constitutive activation of the tyrosine kinase 
activity of these receptors (Holbro et al., 2003; Yarden, 2001). The epidermal growth 
factor receptor (EGFR), belonging to the ErbB family, has a main role in proliferation, 
cell survival and angiogenesis, and the over-expression of the receptor confers 
advantages to tumor cells at different stages of tumor development. EGFR is frequently 
overexpressed in a large number of epithelial tumors, including carcinomas of head 
and neck, breast, colon, lung, prostate, kidney, ovary, brain pancreas and bladder 
(Holbro et al., 2003) and currently EGFR the target of many FDA approved drugs 
(Tebbutt et al., 2013). Cetuximab and Panitumumab are two mAb introduced into 
clinical practice for treatment of metastatic colorectal and head and neck cancer, both 
of them target the external part of the EGFR molecule and inhibit the EGFR-generated 
signaling (Martinelli et al., 2009). 
The epidermal growth factor receptor (EGFR) is a single-chain transmembrane 
protein comprised of an extracellular EGF-binding domain, a short transmembrane 
sequence, and a cytoplasmic region containing a protein tyrosine kinase domain and a 
C-terminal phosphorylation domain. Growth factor binding to the extracellular domain 
of the EGFR (eEGFR) promotes dimerization of the receptor and enhances its intrinsic 
protein tyrosine kinase activity toward intracellular substrates (Holbro et al., 2003). 
In a healthy epithelium the ErbB's receptors have a basolateral location mediating 
signalling between the mesenchyme and the epithelium for cell growth (Yarden, 2001). 
During the development of a tumor, epithelial layers become disorganized and cells 
overexpressing the receptor can be found in the entire tumor volume Figure 2 (Duan et 
al., 2016; Nguyen and Kattan, 2012; Rebouissou et al., 2014).
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Figure 5. EGFR distribution in a healthy epithelia (left)  in comparation with an epithelia 
containing a tumor (right). 
 
These characteristics make EGFR a perfect candidate for targeting bacteria with 
SAs against EGFR  (Gan et al., 2007). In parallel with the development of SAs, the 
host laboratory of the PhD thesis demonstrated that the display of Nbs on E. coli cell 
surface with the intimin Neae domain can be also applied for the selection of high-
affinity Nb clones binding an antigen of interest from libraries of VHHs obtained after 
immunization of camelids with these antigens (Salema et al., 2013a). Lymphocytes are 
isolated from blood samples from the immunized animals and the VHHs are amplified 
by RT PCR for their cloning fused to intimin Neae domain in a plasmid vector (pNeae2) 
and electroporated to E. coli to generate an immune library with ca. 10e7 independent 
clones.  The E. coli display library of Nbs is then incubated with the labelled protein 
antigen (e.g. by biotinylation) and antigen-binding clones selected by magnetic cell 
sorting (MACS) and/or fluorescence-assisted cell sorting (FACS) (Salema and 
Fernandez, 2017). This E. coli display technology was applied to select Nbs binding 
eEGFR (Salema et al., 2016). To this end, VHHs obtained by immunization of two 
llamas with human tumor cell line A431 overexpressing EGFR (Gan et al., 2007) was 
displayed on E. coli with Neae (the final configuration of SAs) and screened for EGFR 
binders using MACS, with biotinylated extracellular region of EGFR fused to human Fc 
(eEGFR-Fc) to capture clones. After selection E. coli clones binding specifically 
eEGFR-Fc by flow cytometry  were selected and the sequence of the clones VHHs 
reveal that five different Nbs were selected. These clones were purified and test in vitro 
to confirm their ability to bind EGFR-Fc and EGFR-expressing cells (Salema et al., 
2016). These Nb clones were then further characterized as part of  this PhD thesis in 
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Material and Methods 
4. 1. Bacterial strains and growth conditions. 
The E. coli strains used in the experiments described in this work are listed in Table 
M1. Bacteria were grown in Luria-Bertani (LB) liquid medium and agar-plates (1.5% 
w/v), at 37°C, unless otherwise indicated. When needed for plasmid or strain selection, 
antibiotics were added to the media at the following concentrations: chloramphenicol 
(Cm) at 30 µg/ml, Kanamycin (Km) at 50 µg/ml and ampicillin (Amp) at 150 µg/ml. E. 
coli DH10B-T1R strain was used as host for cloning and propagation of plasmids with a 
pBR origin of replication (e.g. pNV-derivatives). For cloning and propagation of suicide 
pGE-plasmid derivatives, containing the conditional pi-dependent R6K origin of 
replication (Stalker et al., 1982), the E. coli strains BW25141 or CC118-λpir were used. 
For inducible expression of the SAs from plasmid vectors with plac promoter (i.e. 
pNVgfp, pNVegfr), EcM1 bacteria bearing the corresponding plasmid, were grown in 
LB-Cm at 30°C and 0.05 mM isopropyl-thio-β-D-galactoside (IPTG) was added at an 
optical density 600 nm (OD600) of 0.5. The cultures were further grown for 2 h at 30°C 
with agitation (160 rpm). Bacteria with constitutive expression of the synthetic adhesins 
and the lux operon from the chromosome were always grown statically at 37°C in LB, 
except for minicells-producer bacterial strains that were also grown at 37°C with 
agitation (160 rpm). The number of bacterial generations per day was determined 
according to the formula “Number of generations = (Log Final CFU – Log Initial CFU) / 
Log 2”. 
 
5. 2. E. coli genome modification and strains construction. 
Site-specific deletions and insertions in the chromosome of E. coli were done with 
the marker-less strategy of genome edition based on expression of I-SceI 
endonuclease (Posfai et al., 1999; Posfai et al., 2006).  Briefly, the E. coli strain to be 
modified was initially transformed with plasmid pACBSR (CmR) (Herring et al., 2003), 
expressing I-SceI and λ Red proteins under the control of PBAD promoter (inducible with 
L-arabinose), and subsequently electroporated with the corresponding pGE-based 
suicide vector (KmR). Cointegrants were selected on LB-Cm-Km plates incubated at 
37°C. Individual colonies were isolated and grown for 6 h in LB-Cm liquid medium 
containing L-arabinose 0.4% (w/v) with agitation (160 rpm). After this period, a ~1 µl 
sample of these cultures was streaked on LB-Cm plates using an inoculating loop and 
incubated overnight.  Individual colonies were replicated in LB-Cm and LB-Cm-Km 
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plates to screen for Km-sensitive colonies that have performed resolution of the co-
integrant vector after I-SceI induction. Individual Km-sensitive colonies were screened 
by PCR with specific oligonucleotides (Table M3) to identify those with the desired 
modification in their chromosome (i.e. deletion, insertion, substitution).  Plasmid 
pACBSR was cured from the final strains by growth in liquid LB and streaking on LB-
plates. Individual colonies were replicated in LB and LB-Cm plates to screen for Cm-
sensitive colonies.  
The change of specificity of a SA already integrated in the E. coli chromosome was 
performed by the substitution of the variable part of the SA using the suicide vector 
denominated pGErecomb that contain the new VHH flanked by the homology region 1 
corresponding to the intimin part from the SA structure and the HR 2 from the flu gene 
where is integrated the SA.  For the integration we used the same protocol than before, 
in the Figure 6 we generate a SA against EGFR by substitution of the Vgfp in the 
synthetic adhesin already integrated in the target strain for the Vegfr clonated in the 
plasmid. Construction details of individual E. coli strains are described in Table M1. 
 
Figure 6. Site-specific change of specificity of the synthetic adhesin in the chromosome of E. 
coli. Scheme showing the integration of the vhh against egfr in substitution of the vgfp from the 
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synthetic adhesin express in E .coli. Integration is performed using the pGE Recomb flu-
SA::Vegfr suicide plasmid containing the π dependent R6K origin of replication, a km resistance 
gene (KmR) and the Vegfr gene flanked by HRs, corresponding to 3´´-ends of the eae 
sequence from the SA and the flu gene, and two I-SceI restriction sites. Homologous 
recombination of the suicide plasmid with the chromosome (Recombination I) leads to KmR – 
cointegrants that are later resolved by the expression of SceI endonuclease from the helper 
plasmid pACBSR (Table M2). The double strand breaks, generated by cleavage of DNA with I-
SceI are repaired by a second homologous recombination (RecombinationII) that could either, 
revert the cointegrant to the wild type situation, or lead to chromosomal integration of the Vegfr 
replacing the original Vgfp.  
 
Table M1. Bacterial strains used in this thesis.  
Name Genotype Reference 
DH10B-T1R F- λ-) mcrA Δmrr-hsdRMS-mcrBC φ80lacZDM15 
ΔlacX74 recA1 endA1 araD139 Δ(ara, leu)7697 
galU galK rpsL (StrR) nupG tonA 
Novagen 
BW25141 (F- λ-) Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
Δ(phoB-phoR)580, galU95, ΔuidA3::pir, recA1, 
endA9(del-ins)::FRT, rph-1, Δ(rhaD-rhaB)568, 
hsdR5(F- λ-) Δ(araD-araB)567, 
ΔlacZ4787(::rrnB-3), Δ(phoB-phoR)580, 
galU95, ΔuidA3::pir, recA1, endA9(del-
ins)::FRT, rph-1, Δ(rhaD-rhaB)568, hsdR51(F- 
λ-) Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
Δ(phoB-phoR)580, galU95, ΔuidA3::pir, recA1, 




CC118 λpir Δ(ara-leu) araD  ΔlacX74 galE galK phoA20 thi- 
rpsE rpoB argE(Am) recA1, λpir 
Herrero et al., 
1990) 
MG1655 K-12  (F- λ-)  
EcM1 MG1655ΔfimA-H Salema et al., 
2013) 
EcM1lux SAgfp EcM1∆flu::PN25-SAgfp ∆matB::P2-luxCDABE Carlos Piñero 
thesis 
EcM1lux SAtir EcM1∆flu::PN25-SAtir ∆matB::P2-luxCDABE This work 
EcM1lux SAegfr1 EcM1∆flu::PN25-SAegfr1 ∆matB::P2-luxCDABE This work 
EcM1lux SAegfr2 EcM1∆flu::PN25-SAegfr2 ∆matB::P2-luxCDABE This work 
EcM1 ΔfliSAegfr  Carlos Piñero 
EcM1luxSAegfr∆motA EcM1∆flu::PN25-SAega ∆matB::P2-luxCDABE 
∆yeeJ:: Ptac-gfp ∆motA 
This work 
EcM1luxSAegfr∆flhDC EcM1∆flu::PN25-SAega ∆matB::P2-luxCDABE 
∆yeeJ:: Ptac-gfp ∆flhDC 
This work 
EcM1luxSAegfr∆cheY EcM1∆flu::PN25-SAega ∆matB::P2-luxCDABE 
∆yeeJ:: Ptac-gfp ∆cheY 
This work 
EcM1luxSAega∆cheZ EcM1∆flu::PN25-SAega ∆matB::P2-luxCDABE 
∆yeeJ:: Ptac-gfp ∆cheZ 
This work 
EcM1luxSAega∆nlpE EcM1∆flu::PN25-SAega ∆matB::P2-luxCDABE 
∆yeeJ:: Ptac-gfp ∆nlpE 
This work 
EcM1luxSAega∆dgcZ EcM1∆flu::PN25-SAega ∆matB::P2-luxCDABE 
∆yeeJ:: Ptac-gfp ∆dgcZ 
This work 
EcM1luxSAega∆ycgR EcM1∆flu::PN25-SAega ∆matB::P2-luxCDABE 
∆yeeJ:: Ptac-gfp ∆ycgR 
This work 
EcMini-WT MG1655 ΔminCD Carlos Piñero 
thesis 




EcMini-SAtir EcM1∆fli ∆msbB ΔminCD ∆flu::PN25-SAtir 
∆yeeJ::Ptac-gfp 
This work 




















EcM1∆fli ∆msbB ΔminCD ∆flu::PN25-SAegfr2 
∆yfaL::AraCPBADinvasin ∆yra::PBADllo ∆dapA 
This work 
Salmonella WT Salmonella enterica sv. typhimurium Garcia del 
Portillo lab 




Table M2. Plasmids used in this thesis.  
Name  Relevant properties References 








pGErecombVtir pGE derivative: changing the specificity of a 
SA for the Vtir nanobody 
This Work 
pGErecombVegfr1 pGE derivative: changing the specificity of a 
SA for the Vegfr1 nanobody 
This Work 
pGErecombVegfr2 pGE derivative: changing the specificity of a 
SA for the Vegfr2 nanobody 
This Work 
pACBSR (CmR), p15A-ori, PBAD promoter, I-SceI 
endonuclease,  λRed 
 
pGE∆ypjA::TetRPtetgfp pGE derivative: integration of the gfp in 
substitution of the ypjA E. coli K-12 gene 
under TetR-Ptet control.  
This Work 
pGE∆yfaL::AraCPBADinvasin pGE derivative: integration of the invasin in 
substitution of the yfaL gene from E. coli K-
12 under control of  AraC-PBAD. 
This Work 
pGE∆yra::PBADllo pGE derivative: integration of the llo in 
substitution of the yra E. coli K-12 gene 
under PBAD control. 
This Work 
pGE∆yra::PBADpelB-llo pGE derivative: integration of the llo in 
substitution of the yra E. coli K-12 gene 
under PBAD control. 
This Work 
pGE∆dapA pGE derivative: deletion of the dapA gene 
from E. coli K-12 
This Work 
pGE∆motA pGE derivative: deletion of the motA gene 
from E. coli K-12 
This Work 
pGE∆flhDC pGE derivative: deletion of the flhDC gene 
from E. coli K-12 
This Work 
pGE∆fliCD pGE derivative: deletion of the fliCD gene 
from E. coli K-12 
This Work 
pGE∆cheY pGE derivative: deletion of the cheY gene 
from E. coli K-12 
This Work 
pGE∆cheZ pGE derivative: deletion of the cheZ gene 
from E. coli K-12 
This Work 
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pGE∆nlpE pGE derivative: deletion of the nlpE gene 
from E. coli K-12 
This Work 
pGE∆dgcZ pGE derivative: deletion of the dgcZgene 
from E.coli K-12 
This Work 
pGE∆ycgR pGE derivative: deletion of the ycgR gene 
from E.coli K-12 
This Work 





pSH2 Encoding the fimH operon form UPEC 
strain J96 
(Song et al., 
2007) 
pBAD18ßla Encoding ß-lactamase gene under control 




pBAD18T3SS-VgfpßlaCesT Encoding ß-lactamase gene under control 
of the AraCPBAD promoter with the secretion 







Table M3. Primer list used in this thesis.  
Name  Sequence 
eae 4 CGTAATGGCAATAGCTCTAACAATGTA 
Km seq reverse GCAAACTGATTGGCTGCATTGATG 
ypjA HR5 XhoI CTGGCCCAATCTATATTTGCCCAAC 
ypjA HR5 SacI GTAGTGAAGGCAGCCATCCCGG 
ypjA HR3 SpeI GTATGGAAGTTGAGCCGTGGCTG 
ypjA HR3 SphI GCTGGTATCACTCTGGCCGATGC 
Fw AraC CGGAGATCTTTATGACAACTTGACG 
Rv PBAD GACTCTAGACTCGCAAAAAAACGGG 
Check PBAD Rev AGTTAGGGATTAGCGTCTTAAGCTG 
Check PBAD Fw CTATGCCATAGCATTTTTATCCATA 




Invasin BamHI Rv GGATCCTTATATTGACAGCGCACAG 




LLO SpeI Rv GTGAACTAGTATTATTCGATTGGATTATCTACTTTATTACTATATTTCG 
motA HR5 Rv SacI CGGTCTCGAGCTGAAAACCGGTTTGTG 
motA HR5 Fw XhoI GCAGGAGCTCGACATCATCCTTCCACTG 
motA HR3 Fw SacI GCAGGCATGCGTACAGGCGCAATGG 
motA HR3 Rv SpeI CCGTGAGCTCGAAGAATCAAGCGCATCC 
Check Fw motA GGCATGCTGCCATTCTCAACCG 
Check Rv motA GCATTGGCCCGATCGGCAG 
Check Fw flhCD CGCTGGGGCGTCTTATGAGCC 
Check Rv flhCD CAGCCGCAACAATACCAAACG 
fliCD HR3 Fw GGTGCATGCGGCGTCATAGCGTTCGACGG 
fliCD HR3 Rv ACGGAGCTCCCTGATTAACTGAGACTGACGG 
fliCD HR5 Fw AGGGAGCTCCGTTATAAGTAGCCCTCTGTCCAG 
fliCD HR5 Rv GGTCTCGAGGGGTAACAAGAAGGCAACGG 
Check Fw fliCD GCACCGCATTCACATACGCC 
Check Rv fliCD GCGCCACGGATACGCTGCAC 
cheY 5 XhoI CGGTCTCGAGGCAACTGGCGTTCGATCTCCTG 
cheY 5 SacI ACTGGAGCTCGGATGCGACTATGATGCAACCATC 
cheY 3 SacI TCCGCATCCGAGCTCTTCACACTCCTGATTTAAATACGTATC 
cheY 3 SpeI TAGGACTAGTCAGCATATGCCGCCCGGTTTCACCCGCTCT 
	 42	
Check cheY Fw CGCGTCAGGCTGCCGATGCGC 
Check cheY Rv´ CATCAATATGGGTGGTGTCTG 
cheZ HR5 Fw XhoI CGGTCTCGAGAGTCGCATCCTCACATGCCCAGTTTCTC 
cheZ HR5 Rv SacI TGGGAGCTCGTGGTGTCTGCGAAGTGGTCGATC 
cheZ HR3 Fw SacI CCACGAGCTCCCAGCACCACGCCGCTAATC 
che Z HR3 Rv SpeI TAGGACTAGTTTTGTATTGCCTGATGTGGCGTGA 
Check cheZ Fw CGCGTCAGGCTGCCGATGCGC 
Check cheZ Rv CATCAATATGGGTGGTGTCTG 
dcgZ HR3´ XhoI CGGTCTCGAGCGCTGTTTGTCATCTTAGCG 
dcgZ HR3´ SacI GCAGAGCTCGCTCCGTTTAACATTCATTG 
dcgZ HR5´ SacI GAGCGAGCTCTGCCACTCCTTTTTCACAG 
dcgZ HR5´ SpeI AGGACTAGTGCTCCTCATGCAATAGAAGATGGC 
Check dgcZ Fw GCTAACATCCGCGCGCTGATGAC 
Check dgcZ Rv GTCATGCCTTATGCGTTGGC 
nlpE HR5 Fw XhoI CGGTCTCGAGGGATGGCGTGATCTGGTTATC 
nlpE HR5 SacI Rv GGGGAGCTCCCATTCCTTCTTTTTATCC 
nlpE HR3 SacI Fw TGGGAGCTCCCCTCTTGAGACAGAAACA 
nlpE HR3 SpeI Rv AGGACTCGTGCTGGTGACTCGCCAGATGCTC 
Check nlpE Fw GACAGCGATGGCTGTAATCAG 
Check nlpE Rv GTCGGCGCACCGGTATCCGGA 
dapA HR5 Fw  GGTCTCGAGGAGATTTGATAACGACCACGATACTGCTCG 
dapA HR5 RV Fusion  GACACTTGTTTGCACAGAGGATGGCCCAGTTTAGGGAGATTTGATGGCT
TACTC 
dapA HR3 Fw Fusion  CTAGGACTAGTGCTCGCGCGTCGAAAAGTGCTGTGAAGC 
dapA HR3 RV CTAGGACTAGTGCTCGCGCGTCGAAAAGTGCTGTGAAGC 
 
6. 3. Surface plasmon resonance. 
SPR measurements were performed using Biacore 3000 instrument (GE 
Healthcare). All proteins were dialyzed against HEPES-buffer (20mM HEPES 200mM 
NaCl (pH 7.4) sterile filtered and degassed) at 4ºC o/n. e-EGFR-Fc was immobilized on 
CM5 chip (GE Healthcare) by amino-coupling at 1000 response units (RUs). For 
amino-coupling immobilization EDC/NHS at 5µl/min was injected for 6 min. The 
eEGFR-Fc at 5µG/ml in 10mM AcNa pH 5.0 was injected for 2 min. Finally the 
immobilization was blocked by 1M ethanolamine- HCl, pH 8,5 for 6 min. For 
competition assays eEGFR-Fc was immobilized at 6000 RUs. For this immobilization 
EDC/NHS at 5µl/min was injected for 7 min and blocked with 1M ethanolamine-HCl, pH 
8,5 for 7 min.  
For determination of binding-kinetic dilutions of purified vEGFRs from 0.12 nM 
(vEGFR1), from 0.4 nM to 33 nM (vEGFR2), from 0.14nM to 100nM (vEGFR3), from 
0.41 to 100nM (vEGFR4) and from 0.41 nM to 300 nM (vEGFR5) were injected at flow 
of 30 µl/min and washed with HEPES at the same flow. For competition assays 
vEGFR1-vEGFR4 were diluted to 100nM while vEGFR5 was used at 400nM and EGF 
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at 300 nM. The two competitor molecules were injected sequentially at flow of 30 
µl/min. Sensorgrams were generated and the chip was regenerated each cycle using 
three injections (10µl) of 10mM glycine-HCl pH 2.5. For binding-kinetics, sensorgrams 
with the different concentrations of analyte were overlaid, aligned and analyzed with 
BIAevaluation 4.1 software (GE Healthcare). All data were processed using double-
referencing methods (Myszka, 2000).  
 
7. 4. Flow cytometry analyses.  
Bacteria (equivalent to a final OD600 of 1.0) were harvested from cultures by 
centrifugation (4000 xg, 3 min), washed with PBS and resuspended in 1 ml of PBS 
containing 10% (v/v) goat serum (Sigma).  An aliquot sample of 200 µl was incubated 
for 1 h on ice with anti-myc mAb clone 9B11 (1:200; Cell Signaling Technology). Next, 
bacteria were washed in PBS, resuspended in 500 µl of PBS containing 10% (v/v) goat 
serum, and stained for 40 min in the dark with Alexa 488-conjugated anti-mouse IgGs 
(1:500; Molecular Probes, Life Technologies). Bacteria were finally washed and 
resuspended in a final volume of 1 ml of PBS, and analyzed in a flow cytometer 
(Gallios, Beckman Coulter). 
For cell staining 5X104 cells of the studied cell lines in DMEM supplemented with 
FBS and Glutamine, were seeded onto P6 Thermo Fisher culture plates and grown in 
an incubator at 37º C and 5% CO2 for 24 hours. 
The cells were washed with attemperated DMEM and trypsinized with 1ml of 
tripsin/EDTA 0,05% (Gibco) for 5 minutes. Next the trypsin was neutralize with DMEM 
10%FBS and the cells were washed twice with 1ml of Hank Balance medium 1200 
rpms 3 min and resuspended in 500µl of filtered PBS containing the primary antibody 
anti-EGFR (1µg/ml, Calbiochem) incubated for 1 hour on ice. The cells were washed 
twice with 1ml of filtered PBS and incubated with the secondary antibody goat anti-
mouse Alexa 488 (1:500) in 500 µL volume for an extra hour. Cells were washed twice 
and resuspended in 300µl of filtered PBS for analysis in the flow cytometer (Gallios 
Coulter Beckman).   
 
8. 5. Protein extract preparation, SDS-PAGE, and Western blots. 
WB of phosphorylated Epidermal Growth Factor Receptor (EGFR) was performed 
using Her14 mice fibroblast expressing human EGFR or 3T3 2.2 mice fibroblast 
expressing low levels of mouse EGFR.  
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Cells were seeded in 6-well tissue culture plates (BD Falcon) (~105 cells/well), 
grown for 24 h at 37°C with 5% CO2, grown as monolayer in Dulbecco's modified 
Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and 2 mM 
glutamine (complete DMEM), at 37°C with 5% CO2. After 24 h we removed the media 
and add DMEM media supplemented with 2mM glutamine but without fetal bovine 
serum for 16 hours.  
For detecting EGFR phosphorylation the different treatment with EGFR, EGFR + 
purified Nb anti EGFR or just Nb anti-EGFR were added in DMEM media for 30 
minutes.  
Two different concentrations of Nb´s was employed 30nM or 100nM, in the case of 
the EGF just one concentration was used 15nM in all the cases.  
After the incubation the cells were washed 3 times with 2ml of Hank balance salt 
medium (HBSS Sigma) previously chilled at 4ºC. 
Cells were incubated 30 min shaking 50 rpm´s at 4ºC with 500µl of lysis buffer also 
pre-chilled at 4ºC (50mM Tris-HCl pH 7,4, 1mM EDTA, 150mM NaCl, 1%Triton X100, 
2mM Ortovanadate (Na3VO4), 10mM NaF, 1mM PMSF, Roche complete inhibitor 
EDTA-free). The samples were incubated with the buffer for 30 min and removed with 
the cell scrapper.  
The lysis process was complete passing the samples 4 times through a 25 G 
needle (Microlance 25G 5/8”) using a 1ml syringe and incubating in Eppendorf® tubes 
10 min on ice.  
The tubes were centrifuge for 10 min at 4ºC for 10 min at max speed and recover 
the supernatant.  
Cells extracts were boiled with SDS sample buffer for 15 minutes and charge in a 
SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotting conditions to 
polyvinylidene difluoride membrane (PVDF, Immobilon-P; Millipore) have been 
reported (Bodelon et al., 2009; Bodelón et al., 2009; Salema et al., 2013a). For 
immunodetection, the PVDF-membranes were incubated with anti	Anti-EGFR-P clone 
Y1068 (1:5000; Cell Signaling Technology) to detect the phosphorylated EGFR, and 
anti-rabbit IgG-peroxidase (POD) conjugate (1:5000; Sigma), and with anti-EGFR 
clone 528 which recognize human EGFR (1:5000; Cell Signaling Technology), and 
anti-mouse IgG-peroxidase (POD) conjugate (1:5000; Sigma).  
For bacteria and minicells SAs expression detection, whole-cell protein extracts 
were prepared by mixing 100 µl of a bacterial suspension (OD600 1.0) or minicells 
	 45	
suspension (1,2 x 109 minicells/ml) with 100 µl of PBS (phosphate-buffered saline) and 
2X sodium dodecyl sulfate (SDS) sample buffer or urea-SDS sample buffer 2X. The 
SDS sample buffer contains 60 mM Tris-HCl (pH 6.8), 1% (wt/vol) SDS, 5% (vol/vol) 
glycerol, 0.005% (wt/vol) bromophenol blue, and 1% (vol/vol) 2-ME. The urea-SDS 
sample buffer contains 60 mM Tris-HCl (pH 6.8), 2% (wt/vol) SDS, 4 M urea, 5 mM 
EDTA, 5% (vol/vol) glycerol, 0.005% (wt/vol) bromophenol blue, and 1% (vol/vol) 2-ME.  
(PAGE) was performed by using the Miniprotean III electrophoresis system (Bio-
Rad). 
For immunodetection, the PVDF-membranes were incubated with anti-myc mAb 
clone 9B11 (1:2000; Cell Signaling Technology) to detect myc-tagged SAs and anti-
mouse IgG-peroxidase (POD) conjugate (1:5000; Sigma) as secondary antibody. 
GroEL was detected with anti-GroEL mAb-POD conjugate (1:5000; Sigma) and Omp-A 
with anti-Omp-A polyclonal serum (1:10000) and anti-rabbit IgG-peroxidase (POD) 
conjugate (1:5000; Sigma) as secondary antibody. Membranes were developed by 
measure of chemiluminescence using the Bio-Rad Clarity Western ECL Substrate.  
 
9. 6. In vitro cell culture. 
The epithelial tumor cell lines Her14, 3T32.2, T24 (ATCC), UMUC3 (ATCC), were 
grown as monolayer in Dulbecco's modified Eagle's medium (DMEM Sigma) 
supplemented with 10% FBS (Gibco) and the RT112 (Sigma) and DLD1 (ATCC) cell 
lines in RPMI medium (Sigma) with 10% FBS, while HCT116 (ATCC) human colon 
epithelial tumor cells were grown in Mac Coy´s medium (Sigma) supplemented with 
10% fetal bovine serum (FBS Gibco) grown in the incubator at 37°C with 5% CO2.  
Cells were cultured in T-75 Flask from Falcon and subcultured periodically when 
the cultures reached a confluence of ~80%.  
 
10. 7. Bacterial adhesion assays to in vitro cultured cells and 
immunofluorescence microscopy.  
Bacteria from the indicated E. coli strain were harvested by centrifugation (4000 xg, 
3 min) from static liquid LB cultures grown overnight at 37 oC. An OD600 of 1.0 from 
these cultures grown statically was determined to contain ~3x108 CFU/ml by plating in 
LB-agar. Bacteria were washed in DMEM medium and resuspended at 3x107 CFU/ml 
in DMEM.  For an infection at MOI 300:1, a 1 ml sample of this bacterial suspension 
was added to a single well of a 24-well tissue culture plate having the indicated cell line 
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(~105 cells/well). Cells were grown on sterile coverslips (13 mm diameter, Thermo 
Fisher) placed at the bottom of the well. After 1 h infection at 37 oC, the wells were 
aspirated and washed five times with 1 ml PBS at room temperature. For the adhesion 
assays performed with the flagella mutant strains the infection time was reduced to 30 
minutes. The coverslips were fixed for 20 min at room temperature with 0. 5 ml of a 
paraformaldehyde 4% (w/v) solution in PBS and washed three times with 1 ml of PBS. 
Coverslips were blocked and stained for 1 h at room temperature in a wet chamber 
with 50 µl of PBS-10% goat serum solution, for Her14, 3T3 2.2 cells 
immunofluorescences a rabbit polyclonal serum anti-E. coli O and K antigenic 
serotypes (1:1000; Biodesign) and mouse mAb anti-EGFR (1:500; Calbiochem) was 
used . The coverslips were washed by immersion 10 times in a large volume of PBS 
(100ml), placed again into the wet chamber and incubated for 40 min at room 
temperature with 50 µl of PBS-10% goat serum solution, having a goat anti-rabbit IgG-
Alexa 488 conjugated secondary antibody (1:500; Molecular Probes, Life 
Technologies), anti-mouse IgG-Alexa 594 conjugated secondary antibody (1:500; 
Molecular Probes, Life Technologies) and DAPI (1:500; Sigma).  
For bladder and colon human epithelial tumor cells immunofluorescences, rabbit 
polyclonal serum anti-E. coli O and K antigenic serotypes (1:1000; Biodesign) was 
used. The coverslips were washed by immersion 10 times in a large volume of PBS 
(100ml), placed again into the wet chamber and incubated for 40 min at room 
temperature with 50 µl of PBS-10% goat serum solution, containing goat anti-rabbit 
IgG-Alexa 488 conjugated secondary antibody (1:500; Molecular Probes, Life 
Technologies), Phalloidin Alexa 594 conjugated secondary antibody (1:500; Molecular 
Probes, Life Technologies) and DAPI (1:500; Sigma).  
Next, the coverslips were washed with PBS as above, the excess liquid was 
removed touching a kimwipe with the edge of the coverslip, and mounted with 5 µl of 
Prolong (Invitrogen) on glass slides. The samples were examined by confocal 
microscopy (Leica TCS SP5 multispectral confocal system or Leica TCS SP8 
multispectral confocal system).  
For live cell video microscospy, Her14 cells, grown on 6-well µ-slide (Ibidi), were 
infected with 3x106 CFU of EcM1luxSAegfr, EcM1luxSAegfr∆cheY or 
EcM1luxSAegfr∆cheZ in a final volume ~0.3 ml/well (MOI 30:1). Videos were acquired 
at real time with Yoda (WF-TIRFM) microscopy.  
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8. Bacterial adhesion assays to in vitro cultured cells under flow 
conditions.  
For adhesion assays onto Her14 cells with flagella mutant strains under flow 
conditions, 8,4 x 104 Her14 cells were grown into the Ibidi slide VI0.4 channel in 30 µl of 
media (DMEM supplemented with FBS 10%) for 24 hours. The strains EcM1luxSAegfr, 
EcM1luxSAegfr∆flhCD or EcM1luxSAegfr∆motA from an overnight static culture in LB 
with IPTG for the expression of gfp, were resuspended at 1.0 OD´s/ml and passed 
through the channel at two different flow conditions, 20µl/min and 100µl/min using a 
peristaltic pump. All the samples were examined by the epifluorescence microscopy in 




Figure 7. A. Flow device scheme. Cells were seeded into the bottom of an Ibidi slide VI0.4 and 
the bacteria pumped into the channel, B. Ibidi slide VI0.4 image placed into the microscope.  
 
11. 9. Internalization assay E.coli into human epithelial tumor cells.  
EcM1lux SAegfr2Inva-llo-gfp bacterial strains were harvested by centrifugation 
(4000 x g, 3 min) from static liquid LB cultures grown overnight at 37 oC. An OD600 of 
1.0 from these cultures grown statically was determined to contain ~3x108 CFU/ml by 
plating in LB-agar. Bacteria were washed in PBS and resuspended at 1x107 CFU/ml in 
DMEM with anhidrotetracycline (200 ng/ml) for induction of GFP with the TetRPtet 
promoter for visualizing the bacteria once it is internalized. For the infections at MOI 
30:1, a 1ml sample of this bacterial suspension was added to a single well of a 24-well 
tissue culture plate having T24 or HCT116 cells (~105 cells/well) growing over sterile 
coverslips (13 mm diameter Thermo Fisher), placed at the bottom of the well 48 h 
earlier. After 60 minutes of infection at 37 oC, the wells were aspirated and washed five 




For the invasion of the tumor cells, Arabinose 4% was added to the DMEM media 
for 4 hours extra, anhidrotetracycline is maintained at the same concentration.  
Coverslips were washed five times with 1ml of DMEM each time and fixed in the 
case of the invasion at 4 hours with 4% of paraformaldehyde for 20 minutes. In the 
case of the 24 hours measurement, the cells were incubated with 100µg/ml of 
gentamycin (Gm) for 1,5 hours and overnight with 10 µg/ml of Gm, after this time the 
samples were fixed as before (see Figure 8). 
The coverslips were washed 10 times and placed in a wet chamber and incubated 
for 40 min at room temperature with 50 µl of PBS-10% goat serum solution, having 
rabbit polyclonal serum anti-E. coli O and K antigenic serotypes (1:1000; Biodesign), 
The coverslips were washed by immersion 10 times in a large volume of PBS (100 ml), 
placed again the wet chamber and incubated for 40 min at room temperature with 50 µl 
of PBS-10% goat serum solution, having a goat anti-rabbit IgG-Alexa 546 conjugated 
secondary antibody (1:500; Molecular Probes, Life Technologies), Phalloidin Alexa 660 
conjugated secondary antibody (1:500; Molecular Probes, Life Technologies) and DAPI 
(1:500; Sigma).  
After staining, samples were mounted with 5 µl of Prolong (Invitrogen) on glass 
slides, and examined by confocal microscopy Leica TCS SP5 multispectral confocal 
system or Leica TCS SP8 multispectral confocal system for the actin polymerization 
images.  
Figure 8. Workflow of the internalization assay.  
 
12. 10. LIVE DEAD Cell assay  
For the Live Dead cell assay we repeat the same protocol that is described in the 
Figure 8 and at 24 hours we performed a Live Dead cell staining to check by flow 
cytometry the percentage of dead cells.  
For the staining we recover the supernatant of each well for the cells that were in 
suspension. The attached cells were trypsinized with 300µl of pre-heat trypsin/EDTA 
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0,05% (Gibco- 25300054) for 2 min and neutralized with 300µl of DMEM FBS 10% and 
added to the tube that contains the cells in suspension. The cells were washed twice 
with 1 ml of filtered PBS 1200rpm 3min and resuspended in filtered PBS containing the 
dyes. For preparing the dyes we made a 80-fold dilution of calcein AM (Component A) 
in DMSO to make a 50 µM working solution. The working solution should be used 
within one day. Dye solution was prepared with 2 µL of 50 µM calcein AM working 
solution and 4 µL of the 2 mM ethidium homodimer-1 stock that were added to 1 ml of 
filtered PBS and protected from light.  
Each pellet of already washed cells was resuspended in 300µl freshly prepared dye 
solution and incubated for 30 minutes on ice. The samples were analized using the 
flow cytometer (Gallios, Beckman Coulter). 
 
11. Apoptosis assay. 
For the apoptosis assay we repeated the same protocol but we used Annexin-APC 
and DAPI staining for differenciation of the apoptotic cells against the dead cells. The 
cells were washed with PBS twice and resuspended in PBS with Annexin binding 
buffer 1X at a concentration of 10 million cells/ml. 1µl of Annexin –APC and 1µl of DAPI 
were added to 100µl of the cell suspension and incubated 10min at room temperature 
in the dark. After the incubation, 200µl of filtered PBS was added to each sample 
before their analysis on the flow cytometer (Gallios, Beckman Coulter). 
 
12. ß-lactamase assay.  
The human cell line HCT116 was grown in monolayer up to 80% confluence (2 x 
104cells per well) in DMEM supplemented with 10% of FBS and 2mM glutamine in a 
P96 well plate Black/Clean tissue cultured treated plate from Falcon (353219). The 
medium was removed and cells were washed three times with Hank´s Balance salt 
solution (HBSS Sigma). Next cells were infected with different bacterial strains 
containing plasmids expressing the ß-lactamase gene under AraCPBAD promoter 
control: EcM1luxSAegfr2Inva-llo-gfp, EcM1lux SAegfr2Inva-pelBllo-gfp, EcM1lux 
SAegfr2Inva-llo-gfp∆dapA and SIEC. Bacterial strains were added to the culture at 
30:1 MOI in 200µl of DMEM without glucose (Gibco) for 30 minutes and washed with 
pre-heated HBSS five times. We added DMEM without glucose and supplemented with 
0.4% of arabinose for the induction of ß-lactamase production and invasion for 4 hours.  
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After this time, we washed three times each well with 200µl of HBSS and treated 
the invaded cells with the antibiotic treatment (1,5 hours Gm 100µg/ml and 16 hours 
Gm 10 µg/ml). At 24 hours post-infection the medium was removed and the cells were 
washed three times with HBSS. Next 200µl of HBSS and 20 µl of ß lactamase 
substrate CCF2/AM mix (K1024, Invitrogen) were added to the cells and incubated for 
90 minutes at room temperature in dark. The results were analyzed with the 
SpectraMax iD5 Microplate Reader using the SoftMax Pro software.  
 
13. Minicells adhesion assays to in vitro cultured Her14 cells and 
immunofluorescence microscopy.  
Minicells with the desired SA specificity were harvested by centrifugation (4000 xg, 
20 min) from minicells purifications stored at 4ºC in OptiPrepTM solution (Axis-Shield, 
Scotland) at 4% (w/v) in water, and resuspended at 4x108 minicells/ml in DMEM. For a 
minicell-mammalian cell co-incubation at MOI 500:1, a 250 µl sample of this minicell 
suspension was added to a single well of a 24-well tissue culture plate containing the 
aforementioned Her14 cell line (~105 cells/well) that were grown on sterile coverslips 
(13 mm diameter, Thermo Fisher) placed at the bottom of the well. After four hours of 
co-incubation at 37 oC, the coverslips were washed by immersion 10 times in a large 
volume of PBS (100 ml) to remove unbound minicells. Subsequently, the coverslips 
were treated as in tumor cell lines immunofluorescences carried out in bacterial 
adhesion assays (see Materials and methods, section 7) and examined by confocal 
microscopy (Leica TCS SP5 multispectral confocal system).  
 
14. Minicells purification.  
A 10-ml LB pre-inoculum of the minicell producer strain was grown during 8 hours 
at 37ºC with agitation (160rpm), after that, pre-inoculum was transferred to a flask 
containing one liter of fresh LB that was grown overnight at 37ºC with agitation 
(160rpm). Next day, this one-liter culture of minCD- mutant bacteria was subjected to 
initial differential centrifugation at 550 xg for 40 minutes at 4ºC to decrease the bulk of 
the bacterial burden. The resulting bacterial cell/minicell supernatant was centrifuged at 
4000 xg for 20 min at 4ºC to harvest the bacteria/minicell content, which was 
resuspended in Optiprep (Axis-Shield PLC, Scotland) solution at 4% (w/v) (see below) 
and subjected to two sequential density gradient centrifugation steps using OptiPrep, 
an isotonic biologically compatible medium which is a sterile 60% (w/v) solution of 
iodixanol in water. Gradients were performed with OptiPrep solutions ranging from 20% 
	 51	
to 6% (w/v). After both density gradient centrifugations minicells were found in a low-
density band, whereas bacteria were found in the pellet. The enriched minicell fraction 
still contained some residual bacterial cells that were eliminated after incubating the 
suspension in LB liquid media with agitation for 30 min at 37ºC to reactivate any 
residual bacterial cell and then for 90 minutes in LB liquid media containing gentamycin 
(100 µg/ml) at 37ºC with agitation to kill any live bacterial cell. Lastly, the antibiotic 
treated minicell enriched fraction, was centrifuged at 4000 xg for 20 min at 4ºC and 
resuspended in 4% (w/v) OptiPrep solution and subjected to an additional density 
gradient centrifugation step to eliminate any dead bacterial cell. Purified minicells were 
stored in  OptiPrep 4% solution at 4ºC up to two months. 
 
15. Minicells quantification.  
A method based on minicell protein content determination was developed to 
quantify minicells. A volume equivalent to 6x108 CFU was collected from an overnight 
culture of EcM1luxSAega grown statically at 37ºC, centrifuged at 4000 xg for three 
minutes, resuspended in 200 µl of PBS, sonicated (LabSonic B, Braun) for 40 seconds 
to release protein content and serially diluted using two as dilution factor. Protein 
content in all dilutions was determined with bicinchoninic acid (BCA) protein assay kit 
(ThermoScientific) providing an equation that correlates CFU and protein content. A 
100-µl fraction of the purified minicells solution was treated in the same way to obtain a 
BCA-based protein content estimation in minicells. The equation that correlates protein 
content and CFU enable to determine the number of minicells from the data of protein 
content estimated for them, including a correction factor of five given the size 
difference between bacteria (2 µm) and minicells (0,4 µm). A yield of approximately 
1010 minicells was routinely obtained from one liter culture of minCD-mutant bacteria. 
Acuraccy of this quantification method was confirmed by determining the number of 
minicells in a standard purification with Nanosight’s NS300 device (Nanosight Ltd.), an 







13. 1. Characterization of anti-EGFR nanobodies selected by E. 
coli display 
Previous work in our lab generated an E. coli display library of VHHs after 
immunization of two llamas (Lama glama) with human tumor cell line A431, which 
overexpresses EGFR. From this library a total of five different clones specifically 
binding the extracellular domain of EGFR (eEGFR) were selected and named from 
Vegfr1 to Vegfr5 (V. Salema, 2014 PhD thesis).  After purification of the encoded Nbs, 
we characterized their affinity and the binding properties by Surface Plasmon 
Resonance (SPR). eEGFR-Fc was covalently immobilized to SPR-sensor chip at 
ca.1000 response unit (RUs) and dilutions of the purified Nbs were injected at different 
concentrations (from 0.14 nM to 100 nM) to determine the dissociation constant at 
equilibrium (KD) and the kinetic constants of association (kon) and dissociation (koff). The 
resulting sensorgrams were overlaid, aligned and analysed using 1:1 Langmuir binding 
model (Figure 9). 
According to this analysis, clone VEGFR1 showed the highest affinity for eEGFR-Fc 
(KD=0.47 nM), followed by clones VEGFR2 and VEGFR3 with KDs of ca. 2 nM in both 
cases. Clones VEGFR4 (KD =15.9 nM) and VEGFR5 (KD =24.2 nM) showed a lower 
affinity for eEGFR-Fc.  
Next, we investigated whether these Nbs recognize different epitopes of EGFR by 
analizing their competition for binding to eEGFR-Fc. In this assay the Nbs were 
sequentially injected over the SPR sensor chip in order to record their binding in the 
presence of pre-bound Nbs. As a result we realized that VEGFR1 does not interfere 
with the binding of all other Nbs, indicating that is binding a different epitope of eEGFR 
not recognized by the other clones.  Also Nb VEGFR5 binding was also independent of 
the other Nbs. VEGFR2 blocks the binding of VEGFR3 and VEGFR4 and vice-versa, 
meaning that they bind overlapping epitopes.  
Therefore, these data suggest that at least three different epitopes are recognized 
by the selected anti-EGFR Nbs, one by VEGFR1, a second one by clones VEGFR2, 
VEGFR3 and VEGFR4, and a third one by VEGFR5. The competition assay is shown 
in the Figure 10.  
1.1 Competition of EGF and nanobodies for EGFR binding.  
We investigated whether the selected Nbs could compete with EGF ligand for 
binding to EGFR by SPR. Purified Nbs VEGFR1 to VEGFR5 (100 nM) were injected 
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onto an eEGFR-Fc sensor chip in the presence or absence of EGF (300 nM). The 
sensorgrams showed that EGF does not affect the binding of Nbs VEGFR1 and 
VEGFR5, whereas it reduces the binding of Nbs VEGFR2, VEGFR3 and VEGFR4 to 
roughly half (Figure 11).  
Since clones VEGFR2, VEGFR3 and VEGFR4 compete with each other and with 
EGF these Nbs should likely bind to an epitope partially overlapping the EGF-binding 
site of EGFR or inhibit the conformational change necessary for the receptor to bind 
EGF (Schmitz et al., 2013). On the contrary, Nbs VEGFR1 and VEGFR5 bind to two 
distinct epitopes of EGFR that are independent of EGF binding.  
Figure 9. Determination of the equilibrium dissociation constant (KD) of the selected anti-EGFR 
Nbs using surface plasmon resonance. SPR sensograms monitoring real-time association and 
dissociation of purified Nbs VEGFR1-5 (at concentrations indicated in the color code box) to 
eEGFR-Fc immobilized onto CM5 sensor chip. The increase in resonance units (RUs) was 
recorded along time (in seconds) and dissociation of Nbs was evaluated after the injection of 
the buffer. Sensograms from 2 independent injections are shown. The curve was fitted by non-
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linear least squares regression using the 1:1 Langmuir binding model.  
 
 
Figure 10. Competition of the selected Nbs for binding eEGFR by SPR. Epitope scouting 
analysis of the selected anti-EGFR Nbs (VEGFR1-5) carried out by SPR in pairwise manner to 
identify Nbs that recognize distinct or overlapping epitopes. The eEGFR-Fc antigen is 
immobilized on to the sensor chip and the first analyte (Nb1) is passed over the chip to allow 
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binding to the antigen observed by an increase in response units (RUs) in the sensorgram. 
Subsequently, the second analyte (Nb2) is applied to the Nb1-eEGFR-Fc complex to examine 
its binding. If the second analyte binds a separate epitope, additional binding and hence a 
subsequent increase in RUs in the sensogram is observed. All possible pairwise combinations 





Figure 11.  Competition of EGF and the selected Nbs for binding to eEGFR-Fc determined by 
SPR. SPR sensograms monitoring real-time association and dissociation of the indicated 
purified Nb (VEGFR 1-5) at 100 nM to eEGFR-Fc immobilized onto CM5 sensor chipin the 
presence or absence of pre-bound EGF (300nM). Sensograms are aligned at the point of Nb 
injection. Since EGF start to dissociate from eEGFR-Fc at the time of the Nb injection (see 
sensogram-buffer), this reduction in RUs of the sensrgrams with Nbs when EGF was pre-bound 
does not indicate competition. This is the case of Nbs VEGFR1 and VEGFR5. Higher 
reductions in RUs when EGF was pre-bound are indicative of EGF competition, as is the case 
for Nbs VEGFR2, VEGFR3 and VEGFR4, whose binding is partially abrogated in the presence 
of pre-bound EGF.  
 
	 57	
1.2 Effects of Nbs VEGFR1 and VEGFR2 on ligand-induced EGFR 
phosphorylation. 
EGF and other ligands of EGFR can stimulate cell proliferation, cell differentiation, 
cell growth, migration, and inhibit apoptosis. When the Nbs bind to the extracellular 
domain of this receptor, exist the possibility that the binding alters the phosphorylation 
state of EGFR.  
To characterize the effects of the Nbs in EGFR phosphorylation a WB with anti-
Phospho-EGFR mAb was performed. Her14 cells were treated with EGF, VEGFR1 and 
VEGFR2 separately and with the combination between EGF and the different Nbs.  
Incubation with EGF (15nM) results in the phosphorylation of the receptor, while the 
Nbs by themselves are not able to phosphorylate the EGFR (Figure 12).  
This experiment also shows a partial blocking of the EGFR phosphorylation by the 
VEGFR2.  This is likely due to a direct competition of EGF binding caused by VEGFR2, 
which may reduce the activation of the receptor.  
Figure 12. WB analysis of phosphorylated EGFR (upper lane) and EGFR (bottom lane) and 
upon treatment with Nbs VEGFR1 and VEGFR2. EGFR was detected with anti-EGFR mAb and 
anti-mouse IgG mAb-POD. Phosphorylated EGFR (EGFR-P) with a polyclonal anti-EGFR-P 
(Y1068) and anti-rabbit IgG-POD. The different concentrations of EGF and Nbs used are 
indicated (in µM).  
 
1.3 Construction of synthetic adhesins against EGFR and expression on 
E. coli surface.  
For tumor targeting the Nbs binding EGFR must be displayed on the bacterial 
surface allowing the bacteria to recognize the tumor cells expressing the receptor. 
Previous work in our lab describes the effective display of nanobodies in bacterial 
surface using the Intimin ß-domain that anchored the Nb to the bacterial OM (Salema 
et al., 2013a). The resulting fusion protein was named synthetic adhesin and is 
essential for targeting the tumor cells. The synthetic adhesin structure is shown in the 





























The existence of an E. coli strain already presenting a synthetic adhesin against 
GFP integrated the chromosome, replacing the flu gene (Pinero-Lambea et al., 2015a) 
allow us to generate new strains expressing SAs with other specificities by simply 
exchanging the Nb from the construction.  
This was performed thanks to the pGERecomb-Vegfr1 and pGERecomb-Vegfr2 
suicide plasmids, able to change just the Nb from the previous integrated SAgfp 
(Material and methods, Figure 6).  
The E. coli strain used to express SAs is called EcM1lux. This strain has a deletion 
of the fim operon, encoding the type1 fimbriae, a major adhesin found in most E. coli 
strains. In addition, it carries the lux operon from Photorhabdus luminescens integrated 
replacing the mat operon encoding the conserved Mat fimbriae, also called E. coli 
common fimbriae (ECF) (Rendon et al., 2007).  
Cultures of the resulting strains, EcM1luxSAegfr1 and EcM1luxSAegfr2, grown 
without any inducer or antibiotics, were analyzed by flow cytometry with anti-myc mAb 
to determine the expression levels of the SAs integrated in these strains. Flow 
cytometry data indicated that both SAs against EGFR were displayed on the bacterial 
surface with homogeneous levels in the population (Fig. 13). 
   
Figure 13. Events. Surface display levels 
of SAs in E. coli. Flow cytometry analysis 
of E. coli EcM1lux∆flu, EcM1luxSAegfr1, 
or EcM1luxSAegfr2 bacteria. Histograms 
show the fluorescence intensity of 
bacteria stained with anti-myc mAb and 
secondary anti-mouse IgG-Alexa 488. 
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2. Specific adhesion of engineered E. coli strains to cells lines 
expressing human EGFR.  
2.1 Specific adhesion of engineered E. coli strains to transfected mouse 
fibroblasts expressing human EGFR.  
The ability of EcM1luxSAegfr1 and EcM1luxSAegfr2 bacteria to adhere specifically 
to tumor cells expressing EGFR on their surface was evaluated. To this end, two 
isogenic cell lines derived from the mouse fibroblasts NIH 3T3 cells, termed 3T3#2.2 
and Her14, were employed. 3T3#2.2 cells are devoid of endogenous mouse EGFR 
expression, while Her14 cells are stable transfectants of 3T3#2.2 cells expressing 
human EGFR on their surface (Honegger et al., 1987).  
Subsequently, in vitro adhesion assays with EcM1luxSAegfr1 and EcM1luxSAegfr2 
strains (MOI 300:1) to 3T3#2.2 and Her14 cells were performed. After one hour of 
infection unbound bacteria were removed washing with PBS, and the samples were 
fixed and stain with anti-E. coli polyclonal antibodies. Images of the adhesion assay 
showed that cells positive for EGFR surface expression (i.e. Her14) (red fluorescence) 
were largely covered by EcM1luxSAegfr bacteria (green fluorescence), while in cells 
negative for EGFR expression (i.e. 3T3#2.2) did not have bacteria attached. As a 
negative control another adhesion assay with EcM1luxSAgfp strain was performed 
under the same conditions resulting in a negative adhesion to Her 14 cells. Therefore, 
these data demonstrate that SAegfr1 and SAegfr2 enable specific attachment of 
bacteria to mammalian cells expressing human EGFR. 
Figure 14. SAegfr1 and SAegfr2 drive the specific adhesion of E.coli to EGFR positive cell line. 
Confocal microscopy images of Her14 (top panel) and 3T3 2.2 cells (bottom panel) infected with 
EcM1luxSAegfr1 and EcM1lux SAegfr2 and EcM1luxSAgfp strains. Bacteria were stained with 
anti-E.coli polyclonal serum and anti-rabbit IgG-Alexa 488 (green), EGFR was stained with anti 
EGFR mAb and anti-mouse IgG-Alexa-594 (red), cell nuclei were stained with DAPI (grey). 
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Scale bars (white lines) represent 10 µm.  
2.2 EGFR expression in bladder and colon cancer cell lines. 
Next, we wanted to test whether bacteria with these SAs were able to adhere to 
human carcinoma cell lines expressing endogenous EGFR. Several bladder and colon 
cancer cell lines were employed. Flow cytometry analysis was used to estimate the 
expression of EGFR in bladder tumor cells belonging to different stages of cancer: 
stage I (RT112), stage III (T24 and UMUC 3), as well as colon cancer cell lines DLD1 
and HCT116 both from primary human tumors. As controls we used Her14 cells 
(positive for EGFR) and 3T3 2.2 (negative for EGFR).  
Flow cytometry data showed that all the cancer cell lines used in this assay were 
positive for expression of EGFR, although they expressed significantly less EGFR than 
Her14 cells (Figure. 15). 
Figure 15. Flow cytometry analysis for EGFR expression on (A) bladder tumor cell lines RT112, 
T24, and UMUC3 and (B) on colon cancer cell lines HCT116 and DLD1. Mouse cell lines 3T3 
2.2 and Her14 were used in A and B as negative and positive controls, respectively. Histograms 
show cell counts and fluorescence intensity with anti EGFR mAb and secondary anti-mouse 
IgG-Alexa 488. 
2.3 Specific adhesion of the engineered E. coli strains to EGFR-
positive bladder and colon tumor cells. 
In order to determinate the capability of EcM1luxSAegfr1 and EcM1luxSAegfr2 to 
recognize the EGFR on bladder and colon tumor cells, we performed adhesion assays 
using the EcM1luxSAtir strain as a negative control.  
T24 and UMUC3 bladder cell lines, and DLD1 and HCT116 colon cell lines, were 
employed to this experiment. Cells were infected for an hour with bacteria at a MOI of 
300:1. Unbound bacteria were removed by washing with PBS, and samples were fixed 
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and stained with anti-E. coli polyclonal antibody. Inspection of the samples by confocal 
microscopy revealed high numbers of EcM1luxSAegfr1 or EcM1luxSAegfr2 bacteria 
(red fluorescence) specifically adhered to T24, UMUC3, DLD1 and HCT116 cells 
expressing the antigen EGFR (green fluorescence) on their surface. In the case of the 
colon cell lines, a higher number of bacteria were bound with SAegfr2 (Figure 16B).  In 
contrast, EcM1luxSAgfp bacteria were not bound to those cells. Hence, both SAs 
enable specific adhesion of E. coli to EGFR-positive tumor cells (Figure 16). Since 
SAegfr2 appeared to produce higher adhesion in colon carcinoma cell lines, this SA 





Figure 16. Confocal fluorescence microscopy images of engineered E. coli strains targeting 
EGFR-positive tumor cells. A. Infection of bladder tumor cells T24 and UMUC3. B. Infection of 
colon tumor cells DLD1 and HCT116. Infection carried out with the indicated E. coli strains: 
EcM1luxSAegfr1, EcM1luxSAegfr2 and EcM1luxSAtir. Cell staining was carried out as in Figure 
14.  Scale bars (white lines) showed on the merge pictures represent 10µm. 
 
14. 3. Internalization and content release of bacteria into the tumor 
cells.  
Once our bacteria were able to reach the tumor cells specifically, we investigated 
the use of bacteria as a vector for intracellular delivery of therapeutic proteins (e.g. 
cytotoxins) in the tumor cells. Previous studes showed that a combination of Invasin 
from Yersinia pseudotuberculosis and the listeriolysin (LLO) from Listeria 
monocytogenes can be expressed in E. coli to trigger bacterial internalization and the 
release of RNA or DNA molecules into the host cell cytoplasm (Critchley et al., 2004). 
We attempted to use this combination to deliver directly a protein cargo in tumor cells.  
 
3.1 Invasin expression on E.coli surface.  
Invasins are a class of proteins that permits the penetration of several pathogens 
into the host cells (Palumbo and Wang, 2006). In Yersinia species invasin is a 
fundamental virulence factor required for adherence and colonization of host tissues 
and is encoded in the inv locus in the bacterial chromosome (Dersch and Isberg, 2000; 
Gillenius and Urban, 2015).  
Invasin recognizes ß-integrins expressed on several cell types like leukocytes or 
epitelial cells among others (Anderson et al., 2007). The protein structure consists in a 
ß-barrel-like domain anchored in the bacteria OM, a repeat of immunoglobulin-like 
domains and the C-terminal adhesion domain, which provides the invasin specificity to 
bind the target molecule ß-integrins.  
Invasin used as a natural adhesin does not provide a specific targeting of our 
therapeutical bacteria against tumor cells due to the almost ubiquitous expression of ß-
integrins in human cells (Desgrosellier and Cheresh, 2010). However, the controlled 
expression of invasin after the adhesion with SAs may allow us to invade the tumor 
cells that are specifically recognized by the synthetic adhesin.  With this aim, inv gene 
was integrated replacing the yfaL gene of E. coli K-12, which encodes for an 
autotransporter (Wells et al., 2010). The suicide vector used, pGEyfaL::araC-PBADinv 
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(Figure 17), carries the inv gene under the control of the L-arabinose (L-ara) -inducibe 
promoter PBAD. 
Figure 17. Gene construct for integration of invasin (inv) in the yfaL locus of E. coli K-12 under 
the control of araC-PBAD regulatory region.  
 
To check the invasion of E. coli bacteria expressing inv under araC-PBAD, we 
performed an internalization assay using the EcM1luxSAegfr2 strain carrying araC-
PBADinv construct and expressing GFP in the cytoplasm for detection (yeeJ-PtacGFP). 
An immunofluorescence microscopy-based assay was used to differentiate between 
internalized bacteria and bacteria that remain attached to the tumor cell surface. In this 
assay, called "extracellular staining", cells infected with GFP-expressing bacteria are 
fixed but not permeabilized, so that only extracellular bacteria can be labeled with the 
anti-E. coli polyclonal serum (and secondary Ab conjugated with a fluorophore). Thus, 
intracellular bacteria are only labeled with GFP whereas extracellular bacteria are 
labeled with both anti-E. coli and GFP. 
EcM1luxSAegfr2+inv+gfp strain was used for infection of HCT116 and T24 cells for 
1 h. Non-adherent bacteria were removed by washing and L-ara was added to induce 
the expression of invasin. After 4 h, infected cells were washed, fixed and stained with 
anti-E.coli and secondary anti-rabbit IgG-Alexa 546, phalloidin-660 (actin) and DAPI 
(cell nuclei). Visualization of these samples by confocal microscopy (Figure 18) allowed 
to see internalized bacteria in green and extracellular baceria attached to the cell 
surface in yellow (green+red). In cells treated with L-ara, bacteria were found 
internalized in large clumps, likely due to the polymerization of the ß-integrins around 
bacteria in the cell surface. After 4 h induction of invasin, most bacteria are internalized 
into the tumor cells in samples incubated with L-ara. An important fraction of bacteria 
are also internalized in samples without L-ara, likely due to leaky expression of inv from 
PBAD (Figure 17). However the internalization level observed is lower than that observed 
in samples with L-ara, and being characterized by the absence of clumps of 
internalized bacteria. Therefore, we conclude that there is a successful internalization 
of bacteria in tumor cells due to invasin expression. We also confirmed that invasin 




bacteria (Figure 19). Observation of HCT116 cells 24 h post-infection, allowed to detect 
internalized bacteria with GFP fluorescence at this long incubation time, which suggest 






Figure18. Confocal microscopy of the adhesion and invasion of A. T24 bladder tumor cells and 
B. HCT116 colon tumor cells infected with EcM1luxSAegfr2+inv+gfp (MOI 100:1). Extracellular 
bacteria are stained with anti-E.coli polyclonal and secondary anti-rabbit Alexa 594 (red). All 
bacteria express GFP (green). F-actin in tumor cells is stained with phalloidin 660 (grey). The 






Figure 19. Invasin expression triggers actin polymerization around internalized bacteria. 
Confocal microscopy of actin polymerization during the adhesion and invasion of HCT116 cells 
by EcM1luxSAegfr2+inv+gfp (MOI 30:1). Samples stained as in Figure 18.  
 
 
Figure 20. Confocal microscopy of the invasion of HCT116 colon tumor cells infected with 
EcM1luxSAegfr2+inv+gfp (MOI 100:1) for 24 h. Samples are stained as in Figure 18. The scale 
bar corresponds to 10 µm 
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3.2 Evaluation of apoptosis and cell death triggered by bacterial 
internalization 
Next, we evaluated whether bacterial internalization was inducing tumor cell death 
and/or apoptosis using  two different flow cytometry assays. 
The LIVE/DEAD® Viability/Cytotoxicity Assay provides a two-color fluorescence cell 
viability assay that is based on the simultaneous determination of live and dead cells 
with two probes that measure intracellular esterase activity and plasma membrane 
integrity. Live cells are distinguished by the presence of ubiquitous intracellular 
esterase activity, determined by the enzymatic conversion of the virtually non-
fluorescent cell-permeant calcein-AM to the intensely fluorescent calcein. The 
polyanionic dye calcein is well retained within live cells, producing an intense uniform 
green fluorescence.  Ethidium homodimer-1 (EthD-1) enters cells with a damaged 
plasma membrane and stain nucleic acids producing a bright red fluorescence. EthD-1 
is excluded by the intact plasma membrane of live cells. Figure 13 shows a flow 
cytometry analysis of HCT116 cells infected for 24 h with invasive bacteria 
EcM1luxSAegfr2+inv+gfp in the presence or absence of L-ara. In this assay, cultures 
are treated with gentamycin after 4h infection to kill extracellular bacteria and prevent 
their overgrowth in the culture.  
Data obtained revealed that bacterial invasion of HCT116 cells produces only a 
moderate increase of cell death, from ca. 5.74 % in non-infected cells to ca. 15% in 
infected samples without L-ara and ca. 25% when L-ara is added (Figure 21). 
Figure 21. Cell death after bacterial invasion of HCT116 tumor cells. Flow cytometry of the 
LIVE/DEAD® Viability/Cytotoxicity Assay of HCT116 cells after 24h of infection with 
EcM1luxSAegfr2+inv+gfp in the presence and absence of L-ara, as indicated. Uninfected 
HCT116 cells are used as a control.  
 
During apoptosis, phosphatidylserine (PS) is translocated from the cytoplasmic face 
of the plasma membrane to the cell surface. Annexin V has a strong, Ca2+-dependent 
affinity for PS and therefore can be used as a probe for detecting apoptosis. We 
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performed an invasion assay of HCT116 cells with EcM1luxSAegfr2+inv+gfp, in the 
presence and absence of L-ara, adding gentamycin after 4 h of infection, and 
incubating samples for a total of 24 h. Cell samples from 4 h (before gentamycin) and 
24 h infection were stained with Anexin V-APC and analysed by flow cytometry (Figure 
22). This experiment shows that at 4 h p.i. those cell samples infected with bacteria 
had a strong GFP fluorescence signal, indicating an effective adhesion of bacteria to 
the HCT116 cells, and no induction of apoptosis, with levels of Anexin V-staining 
similar to the uninfected control (Fig. 22). In contrast, at 24 p.i. only the infected sample 
treated with L-ara showed a strong GFP fluorescence signal, as expected for the 
induction of invasin and the internalization of GFP-expressing bacteria, which are not 
killed with gentamycin (Fig. 22). In addition, the highest level of cell apoptosis (18,23 % 
Anexin V-positive cells) was found in samples infected with invasive bacteria, 
compared to uninfected control (2,51 % Anexin V-positive cells) However, the increase 
in Anexin-V-positive cells was no so significant in comparation with infected cells not 
incubated with L-ara (11,98% Anexin-positive cells). Hence, this experiment revealed 
that bacterial invasion of HCT116 tumor cells is very effective after induction of invasin, 
but this massive internaliation is still insufficient by itself to induce a major induction of 
cell apoptosis after 24 h.  
 
Figure 22. Apoptosis of HCT116 tumor cells after bacterial invasion. Flow cytometry assay of 
HCT116 cells at 4 h (A) and at 24h (B) post infection with EcM1luxSAegfr2+inv+gfp in the 
presence and absence of L-ara, as indicated. Samples stained with Anexin V-APC and GFPI. 
Uninfected HCT116 cells are used as a control.  
 
3.3 Evaluation of Listeriolysin O (LLO) for the release of a protein 
cargo into host cells after bacterial invasion. 
Intracellular pathogens have different mechanism to escape from the phagosome 
(Lerena et al., 2010) (Lam et al., 2011). E. coli K-12 does not have any of these 
mechanisms and, indeed, we observed our engineered invasive bacteria intact inside 
	 69	
the tumor cells after 24 h (Figure 20). To attempt the lysis of the phagosome for the 
release of a protein cargo expressed in bacteria, we engineered the expression of 
Listeriolysin-O (LLO) in the chromosome of our invasive E. coli strain. 
LLO is a cholesterol-dependent cytolysin produced by the intracellular pathogen 
Listeria monocytogenes to escape from the phagosome into the host cell. A unique 
LLO feature is a low optimal pH<6 for escape form the phagosome without damaging 
the plasma membrane (Dramsi and Cossart, 2002). The llo gene was amplified from L. 
monocytogenes and cloned without its endogenous signal peptide to allow the 
accumulation of LLO in the cytoplasm of E. coli. In addition, we generated a 
periplasmic version of LLO with the pelB signal peptide form Klebsiella oxytoca 
(Francetic and Pugsley, 2005). Both gene constructs were inserted into chromosome 
of EcM1luxSAegfr2+inv+gfp substituting the fimbrial operon yraHIJK (Jiang et al., 
2010) by using the suicide plasmids pGE∆yraPBADllo and pGE∆yraPBADpelBllo, 
respectively (Figure 23). Thus, addition of L-ara in the resulting strains 
(EcM1luxSAegfr2∆inv∆llo∆gfp and EcM1luxSAegfr2∆inv+pelB-llo∆gfp) should result is 
the simultaneous expression of invasin and LLO in the bacteria. 
 
 
Figure 23. LLO constructs for integration in the yra site of E. coli chromosome under control of 
the PBAD promoterwith and without the signal peptide pelB.  
 
Lastly, since cytoplasmic LLO does not have access to the phagosome membrane 
before bacterial lysis, we deleted the dapA gene in EcM1luxSAegfr2∆inv∆llo∆gfp to 
accellerate bacterial lysis. The dapA gene encodes the 4-hydroxy-
tetrahydrodipicolinate synthase required for the syntheis of the essential peptidoglycan 
component diaminopimilic acid (DAP). Thus, ΔdapA strains are auxotrophic and 
present inestability of the cell wall in the absence of DAP in the medium (Critchley-
Thorne et al., 2006).   
To detect and quantify the release of a protein cargo in tumor cells after bacterial 
invasion, we used the reporter enzyme TEM-ß-lactamase (BlaM) devoid of signal 
	 70	
peptide. The activity of BlaM can be specifically detected and quantified in the 
cytoplasm of the mammalian cells, but not in the cytoplasm of the producing bacteria, 
with the substrate CCF2 (Charpentier and Oswald, 2004). CCF2 is a fluorescence 
resonance energy transfer (FRET) substrate, which consist of a cephalosporin core 
linking 7-hydroxycoumarin to fluorescein. CCF2-AM is a non-fluorescent lipophilic 
esterified form of CCF that allow its readily entry into cells. Cytosolic esterases 
specifically present in mammalian cells rapidly converts CCF2-AM into its negatively 
charged form, CCF2, which is retained in the cytosol.  
In the absence of BlaM activity, exciting the coumarin at 409 nm in the intact CCF2 
molecule results in FRET to the fluorescein, which emits a green fluorescence signal at 
518 nm. In the presence of BlaM activity, however, cleavage of CCF2 disrupts FRET, 
so that exciting the coumarin at 409 nm now produces a blue fluorescence signal at 
447 nm. This blue signal can be detected as an increase in the blue channel readout 
on fluorescence microplate readers. 
For this experiment we seeded HCT116 cells in 96 wells plates at 80% of 
confluency, and were infected with our bacterial strains expressing inv and llo (Inv-llo), 
inv and pelB-llo (Inv-pelBllo), the auxotrophic mutant Inv-llo-ΔdapA. These strains were 
transformed with the pBAD18-BlaM that expresses cytoplasmic BlaM under control of 
the L-ara inducible araC-PBAD promoter. Infection with these strains (MOI 30:1) in the 
presence of L-ara was conducted for 4 h and 24 h, in the latter case adding 
Gentamycin after 4 h. As a positive control we used the Synthetic Injector E. coli 
(SIEC) strain previously constructed in our lab (Ruano-Gallego et al., 2015), which 
encodes the injectisomes of the type III secretion system (T3SS) of enteropathogenic 
E. coli (EPEC). The SIEC strain was transformed with the plasmid pBAD18-T3S-BlaM 
that encodes a fusion of a T3S-signal to BlaM for the direct injection of the enzyme into 
the cytosol of mammalian cells through the injectisomes (Charpentier and Oswald, 
2004). Infection of HCT116 cells with SIEC (MOI 30:1) was conducted for 4 h adding 
IPTG and L-ara to induce the expression of T3SS injectisomes and T3S-BlaM, 
respectively. In addition, a 24 h sample of this infection was also obtained by addition 
of Gentamycin after the initial 4 h of infection. Treatment with Gentamycin kills 
extracellular bacteria, as is the case of SIEC bacteria (Ruano-Gallego et al., 2015). All 
samples, from 4 h and 24 h infections, were incubated with CCF2-AM for 90 min and 
their fluorescence emission at 447 nm and 518 nm were measured. The results from 
these assays shows that, after 4 h infection, only the cells infected with the positive 
control SIEC strain, and none of invasive strains, had a clearly detectable BlaM activity 
in the cytosol above the background of uninfected cells (Figure 24).  After 24 h 
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infection, however, cells infected with the invasive strains, especially Inv-llo-∆dapA 
strain, showed a weak increase in the BlaM activity above the background levels of 
uninfected cells (Figure 24). At 24 h infection time, only a residual activity of BlaM was 
detected in cells infected with SIEC. This was expected due to the Gentamycin 
treatment, which killed SIEC bacteria at 4 h of infection and then the injected BlaM 
levels are likely diluted due to proteolysis and cell growth. Hence, the invasive strains 
with LLO, especially the Inv-llo-∆dapA strain, are able to release a protein cargo in the 
cytosol of tumor cells after 24 h of infection, although at low levels, representing ca. 15 
to 30% of those injected in 4 h by the SIEC strain.  
Figure 24. Graphic for translocation of ßlactamase to the cytoplasm of HCT116 cells infected 
for 4 hours or 24 hours with the tested invasive bacterial strains, As a control we measured the 
injection of ßla by the SIEC strain and the non–infected cells.  
 
3.4 Induction of a protein cargo in bacteria after invasion of tumor 
cells. 
We also checked the capability of the internalized bacteria to induce a protein 
cargo. As a proof-of-concept the gfp gene was cloned under control of the tetR-PtetA 
promoter (Bertram and Hillen, 2008) for induction with anhydro-tetracycline (aTc). The 
construct was cloned in the suicide vector pGEypjA::tetR-PtetA-gfp for insertion in the 




























































An adhesion-invasion experiment of HCT116 cells was performed with L-ara for 4 h 
followed by Gentamycin treatment for additional 1 h at 100µg/ml. Next, aTc was added 
or not (as a control) and infection continued for additional 2 h. Samples were fixed and 
stained with anti-E. coli, phalloidin, and DAPI (Figure 25). This experiment showed that 
intracellular bacteria strongly expressed GFP, demonstrating that a protein cargo can 
be induced in the bacterium after cell invasion.  
Figure 25. Induction of a bacterial protein cargo in the phagosome of tumor cells. Confocal 
microscopy of HCT116 colon tumor cells infected with EcM1luxSAEGFR2PBAD-invPtet-
gfp∆ypjA::TetRPtet gfp (MOI 100:1) for 4 h in the presece of L-ara and with gentamycin for 
additional 1 h. Then, aTc was added or not (control) to induce GFP expression in the 
internalized bacteria. Samples stained with phalloidin and DAPI to visualize actin (red) and cell 
nuclei (grey). Bar = 10 µm.  
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4. Synthetic adhesins against EGFR-tumor cells in non-live E. 
coli minicells.  
In addition of live bacteria as delivery vectors for therapeutic molecules to tumor 
cells, non-live bacterial derived minicells could be appropriated for this aim (Flemming, 
2007; MacDiarmid et al., 2007; Tsuji et al., 2016; Xin et al., 2017). An E. coli strain 
producing minicells (EcM1∆minCD ∆fliCD ∆msbB), called EcMini, was previously 
constructed in the laboratory (Piñero-Lambea, 2014, PhD thesis). Deletion of minCD 
results in the generation of minicells. Deletion of fliCD, encoding the flagellin and 
flagellar cap protein, and msbB (also known as lpxM), responsible of the normal hexa-
acylation of lipid A, reduce the innate immune response against flagella and LPS 
(Brubaker et al., 2015; Rosadini and Kagan, 2017; Somerville et al., 1999). The EcMini 
strain was used to generate minicells expressing SAs against EGFR on their surface 
and a protein cargo in their cytoplasm. 
 
4.1 Generation of minicells with synthetic adhesins and a cargo 
protein. 
SAs binding human EGFR and Tir from EHEC, as negative control, were integrated 
at the flu site of EcMini chromosome (Material and Methods 2).  
Minicells were isolated in the supernantat from cultures of EcMini-SAegfr and 
EcMini-SAtir strains by differential centrifugation at low speed followed by density 
gradient centrifugations. Lastly, a Gentamycin treatment was used to kill any residual 
bacteria (Material and Methods 14). Purified minicells preparations were plated in LB 
agar to confirm that they were free of viable bacteria (data not shown). Using this 
methodology, we routinely purified ca. 6 x 109 minicells per liter of culture at OD600=1.  
Western blot analysis of purified minicells and producing bacteria (Figure 26) 
confirmed the presence of SAs anti-EGFR and anti-Tir in the minicells of EcMiniSAegfr 
and EcMiniSAtir, respectively, and not in the parental strain EcMini. We also confirmed 
that minicells contained normal levels of bacterial proteins such a OmpA (OM porin) 
and GroEL (cytoplasmic chaperonin). Lastly, we demonstrated the display of SAs anti-
EGFR and anti-Tir on the surface of the purified minicells EcMiniSAegfr and 
EcMiniSAtir by incubation with anti-myc mAb and secondary anti-mouse IgG-Alexa 488 
(green) followed by fluorescence microscopy (Figure 27). Therefore, the purified 
minicells are made up of the protein content of the parental bacterial cells and display 
the SAs on their surface. 
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Figure 26. Synthetic adhesins expressed in E. coli minicells A. Western blot of complete protein 
extracts from bacteria and purified minicells (from the indicated strains) probed to detect: SAs 
(anti-myc mouse mAb and anti-mouse IgGs-POD; top panel), OmpA porin (anti-OmpA rabbit 
polyclonal serum and anti-rabbit IgG-POD; middle panel), and GroEL chaperonin (anti-GroEL 
mAb-POD). B. Fluorescence microscopy images of purified minicells from EcMini, 
EcMiniSAegfr, EcMiniSAtir strains, as indicated, stained with anti-myc mAb and secondary anti-
mouse IgG-Alexa 488 (green) to detect SAs on the surface of the minicells 
Figure 27. Minicells with GFP as a cargo protein. Bright field (left) and fluorescence microscopy 
(right) images of minicells purified from EcMiniSAegfr-Ptac-gfp strain induced with IPTG 
showing GFP expression in the cytosol.  
Next, we generated "cargo-loaded" minicells using GFP as a model cargo protein. 
A Ptac-gfp construct was inserted in the chromosome of EcMiniSAegfr by substitution 
of yeeJ locus using the suicide vector pGE∆yeeJ::Ptacgfp. During the bacterial growth 
we are able to accumulate the GFP in the bacterial cytoplasm by induction with IPTG 
and the minicells obtained after purification (MiniSAegfr-GFP) contained GFP in the 
cytoplasm (Figure 28).  
Figure 28. Adhesion of minicells with synthetic adhesins to Her14 (EGFR+) and 3T3 2.2 
(EGFR-) cells. Confocal images of Her14 and 3T3 2.2 cells incubated with minicells MiniSAegfr-
GFP and MiniSAtir-GFP for 4 h (MOI 500:1). Samples were stained with anti-EGFR (red) and 
DAPI (grey). Minicells contain GFP (green). 
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15.1.1 4.2. Adhesion of the engineered minicells to tumor cells 
We tested the capability of the engineered minicells to recognize and bind the 
target molecule on the surface of tumor cells. Minicells from E. coli strains 
EcMiniSAegfr-Ptac-gfp and EcMiniSAtir-Ptac-gfp, as a negative control, were 
incubated for 4 h with Her14 (EGFR+) and 3T3 2.2 (EGFR-) cells (MOI 500:1). 
Unbound minicells were washed and the samples were fixed, stained with anti-EGFR 
mAb and DAPI, and inspected by fluorescence microscopy (Figure 28). This 
experiment revealed that only a few minicells MiniSAegfr-GFP adhere to Her14 cells. 
In addition, a similar number of minicells were bound to the control cell line (3T3 2.2) 
and minicells (MiniSAtir-GFP).  
To test whether longer incubation times could improve adhesion, we performed an 
identical in vitro adhesion assay to Her14 cells incubated with MiniSAegfr-GFP and 
MiniSAtir-GFP for 4 h and 16 h (Figure 30). Although a higher number of minicells 
MiniSAegfr-GFP were able to bind Her14 cells at 16 h, adhesion of control minicells 
MiniSAtir-GFP also increased. Hence, despite the higher MOI and longer times of 
incubation, these experiments indicated an apparent inability of minicells with SAs to 
bind effectively to target cells. This result dramatically contrast with our previous data 
using live E. coli bacteria expressing SAs (Figure 14).  
Figure 29. Adhesion of minicells with synthetic adhesins to Her14 (EGFR+) cells at long 
incubation times. Confocal images of Her14 cells incubated with minicells (MOI 500:1) 
MiniSAegfr-GFP and MiniSAtir-GFP for 4 h (left) and 16 h (right). Samples were stained with 
anti-EGFR (red) and DAPI (grey). Minicells contain GFP (green).  
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16. 5. Influence of bacterial flagella in the adhesion to tumor cells 
The poor adhesion to tumor cells achieved by minicells prompted us to investigate 
which specific property present in live bacteria is responsible of their extreme efficient 
adhesion capacity. There are many important differences between minicells and the 
parental live bacteria, including size (four times smaller, size of minicells; 400nM 
)(MacDiarmid et al., 2007), lack of chromosomal DNA, and of an active metabolism 
and flagella.  In the video number 1 shows an in vitro adhesion assay performed with 
WT strain EcM1 SAegfr2 and the tumor cell line Her14, in which motile bacteria are 
seen touching different points of the cells before establishing a permanent adhesion 
event. These type of microscopic observations suggested that the chance of finding a 
receptor might be increased by the flagellar motility, which doesn’t not exist in the 
minicells. Flagella is the principal motility organelle in E.coli and other bacteria and it 
has been shown to be important for the adhesion of pathogenic bacteria to host cells 
(Duan et al., 2013; Haiko and Westerlund-Wikstrom, 2013) and and abiotic surfaces in 
biofilm formation (Belas, 2014; Friedlander et al., 2015). Based on these preceding 
reports and observations, we decided to focus on flagella and its role during the 
adhesion of our engineered bacteria to target tumor cells.  
5.1. Adhesion of flagellar mutant bacteria to tumor cells 
We constructed several mutant strains having deletions in genes related with the 
synthesis of flagella. First, we recreated in EcM1SAegfr strain the ΔfliCD mutation 
found in the E. coli strains producing the minicells. The fliCD genes encode the flagellin 
(FliC) and the flagellar cap protein (FliD) (Inaba et al., 2013). We tested the adhesion 
capability of the parental "WT" and ΔfliCD strains to Her14 cells (EGFR+). Bacteria 
were added to Her14 cells for 30 minutes (MOI 300:1), washed with PBS and stained 
for fluorescence microscopy (Figure 30). 
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Figure 30. Adhesion to EGFR+ cells of engineered bacteria with wild type and mutant flagella. 
Confocal microscopy images of Her14 cells infected with EcM1luxSAegfr (WT) and isogenic 
mutant ∆isoge. Infection and staining actin (red) E.coli contains GFP under control of Ptac 
promoter for visualization in green. Cell nuclei and bacterial chromosomes were stained with 
DAPI (grey). Scale bar = 10 µm. 
 
This experiment clearly shows that bacteria lacking flagella are not able to attach to 
Her 14 cells while motile bacteria adhere in high numbers. This result points out 
flagella as an essential piece in the adhesion process. 
Although the flagellum has been traditionally regarded as a motility organelle, it has 
also been suggested to have an adhesin role in various pathogenic strains of E. coli, 
Pseudomonas aeruginosa and Clostridium difficile (Duan et al., 2013; Giron et al., 
2002).   
The role of flagella as an adhesin assisting the attachment of bacteria harboring 
SAs against EGFR was tested by constructing deletion mutants lacking the whole 
flagellar apparatus (∆flhDC) and abrogating motility (∆motA).  The flhDC operon 
encodes a master regulator required for the expression of all the flagellar components 
(Gauger et al., 2007; Liu and Matsumura, 1994). The motAB operon encodes integral 
inner membrane proteins that form the stator of the flagellar motor, thus ∆motA 
mutants express flagellar filaments unable to rotate (Blair and Berg, 1990; Hosking et 
al., 2006).  
The motility of the parental EcM1SAegfr (WT, positive control) and its deletion mutant’s 
∆motA and ∆flhDC strains was evaluated in soft LB-agar plates. As a negative control 
this assay also contained the non-motile EcM1∆fliCD strain. As expected, only the WT 
strain was able to swim in soft agar (Figure 31A). Coomassie staining of extracellular 
proteins from culture supernatants of these strains (Figure 31B) confirmed the absence 
of flagellar proteins FliC and FliD in the deletion mutants ∆fliCD and ∆flhDC, whereas 
these filament components are present in both the non-motile ∆motA mutant and the 
parental (WT) strain. We also showed that these deletions did not affect the expression 
of the synthetic adhesin on the bacterial surface (Figure 32A.), or the recognition of the 




Figure 31. A. Motility assay on soft-agar plates of EcM1SAegfr strain (WT) and its mutant 
derivatives ∆motA and ∆flhDC. Bacteria were grown in a soft-agar (0.3 %) LB plate for 8 hours 
at 37°C. B Coomassie staining of SDS-PAGE (12%) having protein samples from culture 
supernants of the strains EcM1SAegfr (WT) and isogenic mutants ∆motA and ∆flhDC. 
EcM1∆fliCD was used as a non-motile control (A and B). 
Figure 32. Surface display levels and functionality of SAs expressed in flagellar mutants of E. 
coli. Flow cytometry analysis of E. coli EcM1 (negative control; grey), EcM1SAegfr (WT), and 
isogenic ∆motA and ∆flhDC bacteria. Histograms shows the fluorescence intensity of bacteria 
stained with A. anti-myc mAb and secondary anti-mouse IgG-Alexa 488. B. biotinylated 
eEGFR-Fc and the secondary Streptavidin-APC.  
Next, we tested adhesion of the above bacterial strains to Her14 cells (EGFR+). As 
a negative control of binding we used a flagellated WT strain expressing an unrelated 
SA (EcM1SAtir). Our results show that only the motile WT bacteria expressing SAegfr 
adhere to Her14 cells (Figure 33) which underlines the requirement of an active 
flagellar motor for the adhesion of E. coli to tumor cells. 
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Figure 33. Adhesion of bacteria to target tumor cells requires an active flagellar motor. Confocal 
fluorescence microscopy images of the adhesion to Her14 (EGFR+) cells of E. coli strains 
EcM1SAegfr and isogenic ∆flhDC and ∆motA mutants. Cells were infected with bacteria (MOI 
300:1) for 30 min and washed with PBS to remove unbound bacteria.  Samples were stained to 
visualize actin (red), and DAPI (grey). Bacteria (green) express GFP from plasmid pGEN22 
(REF). Scale bars =10 µm. 
 
5.2 Importance of the sense of flagellar rotation for bacterial adhesion 
The flagella motor rotates both clockwise (CW) and counterclockwise (CCW), which 
regulates the swimming pattern of bacteria (Xie et al., 2011). When all flagellar motors 
spin CCW, the bacterium presents all flagellar filaments in a single bundle a linear 
swimming occurs (run mode). In contrast, when the motors spin CW, the flagellar 
filaments spread in opposite directions and make the bacterium to tumble (tumble 
mode). Tumbling allows the bacterium to change its swiming direction randomly when 
reenters in the run mode. The frequency and time of CCW and CW rotation of flagellar 
motors is regulated in response to environmental stimuli generating positive 
chemotaxis to attractants and negative chemotaxis to repellents (Terashima et al., 
2008). Both modes of bacterial swimming are necessary for the movement of bacteria 
towards environments that are favorable for growth and survival (chemotaxis), but it 
has not been described if these movements are important for bacterial adhesion to 
host cells.  
Hence, we generated two deletion mutants from the EcM1SAegfr strain obtaining 
chemotactic mutant bacteria that only swims in a linear direction (∆cheY) and bacteria 
that only tumble (∆cheZ). The cheY and cheZ genes belongs to the chemotaxis 
regulators of E. coli, which are in charge of controlling the sense and duration of 
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rotation of flagellar motors (Belas, 2014). As a result of the presence of a repellent, 
CheY is phosphorylated (CheY~P) by specific receptors and interacts with the flagellar 
motor promoting the tumbling movement. CheY~P is dephosphorylated by CheZ and 
the linear swimming is restored (Akhter and Amin, 2017). We showed that in liquid LB 
medium, EcM1SAegfr ∆cheY and ∆cheZ strains have the expected phenotypes (see 
videos 2 and 3), with cheY deletion mutant only swimmin g linearly and the cheZ 
deletion mutant only tumbling. Also as expected, the cheY and cheZ mutants from 
EcM1SAegfr strain were non-motile in soft-agar plates (Figure 34), which confirms the 
absence of chemotactic movement in both mutants. In addition, we confirmed normal 
surface display levels and binding activity of SAegfr on ∆cheY and ∆cheZ mutants 
(Figure 34) 
 
Figure 34. A. Motility and synthetic adhesin expression of chemotaxis mutants. Motility assay 
on soft-agar plates of EcM1SAegfr strain (WT) and its mutant derivatives ∆cheY and ∆cheZ. 
Bacteria were grown in a soft-agar LB plate for 8 hours at 37°C. Wild-type motility of EcM1SAtir 
strain is also shown. B. Surface display levels and functionality of SAs expressed in chemotaxis 




(WT), and isogenic ∆cheY and ∆cheZ bacteria. Histograms shows the fluorescence intensity of 
bacteria stained with anti-myc mAb and secondary anti-mouse IgG-Alexa 488 (left pannel) and 
biotinylated eEGFR-Fc and the secondary Streptavidin-APC (right).  
 
We tested adhesion of chemotaxis mutants to Her14 (EGFR+) cells and found that 
∆cheY bacteria were able to bind to cell surface whereas ∆cheZ bacteria could not 35 
This result suggested that a linear movement of the bacterium was needed for 
adhesion to the tumor cell surface. Microscopic inspection of these samples allowed us 
to conclude that bacteria lacking linear swimming were not able to reach the bottom of 




Figure 35. Adhesion of chemotaxis E. coli mutants to target tumor cells. Confocal fluorescence 
microscopy images of the adhesion to Her14 (EGFR+) cells of E. coli strains EcM1SAegfr and 
isogenic ∆cheY and ∆cheZ mutants..Samples were infected and stained as in Figure 25. Actin 
(red), bacteria (green) and cell nuclei (grey). Scale bars =10 µm. 
 
To force the contact of bacteria to the tumor cells,  we performed adhesion assays 
in which bacteria and cells were centrifuged at low speed on the culture plate (4000 
rpm, 2 min), thus allowing bacteria to reach the bottom of the plates. In this 
experimental setup, the ∆cheZ mutant was able to bind the Her14 cells at similar levels 
as the WT and ∆cheY bacteria (Figure 36). Forcing cell contact by centrifugation of 
∆flhDC and ∆motA strains was insufficient to fully restore adhesion (Figure 36).  
Although some improvement was observed in these strains, the background adhesion 
of the control strain (EcM1SAtir) was also significantly higher. Therefore, the flagellar 
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rotation in at least one direction (CCW or CW) is required for an efficient adhesion of 
bacteria upon cell contact.  
Figure 36. Forcing cell contact by centrifugation does not substitute the need of flagellar 
rotation. confocal microscopy images of Her 14 cells infected with EcM1SAtir (negative control), 
EcM1SAegfr (WT flagella), and isogenic ∆cheY, ∆cheZ, ∆flhDC, and ∆motA bacteria. Bacteria 
and cells were centrifuged (2000 rpm, 4 min). and incubated for additional 30 min at 37 oC.  
Samples were stained to visualize actin (red) and cell nuclei (grey). Bacteria (green) express 
GFP in their cytoplasm. Scale bars=10 µm. 
 
5.3 Adhesion assays under flow conditions to force cell contact 
We explored the possibility of restoring the attachemnt to cells of ∆flhDC and 
∆motA mutants using an adhesion assay under unidirectional flow conditions, which 
could mimick the unidirectional swimming of ∆cheY bacteria. For these experiments, 
Her14 cells were grown on slides with microchannels (IBIDI channel µ-slides VI 0.4) 
and bacteria were passed in media at two different flow rates (Figure 29 nueva). A flow 
rate of 20 µl/min, corresponding to a shear stress of 0.025 dyn/cm2, and a flow rate of 
100 µl/min, corresponding to a shear stress of 0.126 dyn/cm2 . The shear stress 
(τ)  was calculated according to the formula τ=η•176.1•φ  for this type of chamber h is 
the dynamical viscosity of the media (0.0072 dyn·s/cm2 for DMEM with 10% of serum 
at 37°C) and f the flow rate).  
Bacteria were passed for 30 min and then the channels were washed with media 
for additional 5 min at identical flow rate. In both cases, we found that WT bacteria 
(EcM1SAegfr) adhered to Her14 cells whereas ∆motA and the ∆flhDC strains were not 
able to attach under any condition (Figure 30 nueva A and B). These phenotypes are 
observed in videos 4, 5, and 6. Taken together, these results strongly indicate an 
important role of the activity of the flagellar rotor for bacterial adhesion upon cell 




Figure 37. Adhesion assays under unidirectional flow conditions. Bright field and fluorescence 
microscopy images of Her14 cells infected with EcM1SAtir (negative control), EcM1SAegfr 
(wild-type flagella), and isogenic ∆flhDC, and ∆motA bacteria (as indicated). Bacteria express 
GFP (green) and were applied for 30 min with media at a flow rate of 20 µl/min (A) or 100 µl/min 
(B). Scale bar =10µm.  
 
5.4 Evaluating flagellar mechanosensing in bacterial adhesion. 
We hypothesized that that flagellar rotation could trigger a signaling cascade in the 
bacterium that may facilitate the attachment to the tumor cell surface. It has been 
reported that mechanosensing of surfaces in bacteria is a process that often uses 
obstruction of flagellum rotation to trigger behaviors such as adhesion and surface-
associated movement (Ellison and Brun, 2015). In E. coli, an outer membrane 
lipoprotein, called NlpE (Delhaye et al., 2019), is reported to be able to sense a 
mechanical contact to a solid surface and activate a poorly characterized signalling 
pathway to pause the flagellar motor . This results in an increase in c-di-GMP levels in 




et al., 2010; Lacanna et al., 2016). A major enzyme involved in c-di-GMP production in 
E. coli is DgcZ (Lacanna et al., 2016). 
To explore whether this mechanosensing pathway participates in the adhesion 
process to cells, we generated deletion mutant strains ∆nlpE, ∆ycgR, and ∆dgcZ 
derived from our motile wild type EcM1SAegfr strain. These mutant strains were motile 
in soft agar at the same level as EcM1SAegfr (Figure 38) and expressed functional 
synthetic adhesins on the bacterial surface (Figure 38).  We also confirmed the 
expected phenotype of ∆ycgR by overproducing in this mutant the diguanylate cyclase 
enzyme AdrA from Salmonella enterica sr. typhimurium (Cowles et al., 2016). 
Overxpression of AdrA increase the level of di-c-GMP and stops rotation of flagella by 
interaction with YcgR (Zorraquino et al., 2013). Induction with AdrA expression from 
plasmid pBADadrA inhibits the motility of the wild type EcM1SAegfr but not of the 






Figure 38. Motility and synthetic adhesin expression of flagellar mechanosensing mutants. A. 
Motility assay on soft-agar plates of EcM1SAegfr strain (WT) and its mutant derivatives ∆nlpE, 
∆ycgR, and ∆dgcZ. Bacteria were grown in a soft-agar LB plate for 8 hours at 37°C. Wild-type 
motility of EcM1SAtir strain is also shown. B. Surface display levels and functionality of SAs 
expressed in mechanosensing mutants of E. coli. Flow cytometry analysis of E. coli EcM1 
(negative control; grey), EcM1SAegfr (WT), and isogenic ∆nlpE, ∆ pE1, and ∆dgcZ bacteria. 
Histograms shows the fluorescence intensity of bacteria stained with anti-myc mAb and 
secondary anti-mouse IgG-Alexa 488 (left pannel) and biotinylated eEGFR-Fc and the 
secondary Streptavidin-APC (right).  
 
Figure 39. Inhibtion of flagellar motility by di-c-GMP production is dependent on YcgR. Motility 
in sofr-agar plates of EcM1SAegfr and ∆ycgR strains carrying pBADadrA grown in the absence 
(-) or presence (+) of L-arabinose (Ara). The strain EcM1∆fliCD is included as a non-motile 
control. 
Next, we performed an standard in vitro adhesion assay to cells and found that 
∆nlpE, ∆ycgR, and ∆dgcZ deletion mutants attached to Her14 cells at the same level 




Figure 40. Adhesion of mechanosensing E. coli mutants to target tumor cells. Confocal 
fluorescence microscopy images of the adhesion to Her14 (EGFR+) cells of E. coli strains 
EcM1SAegfr and isogenic ∆nlpE, ∆ycgR, and ∆dgcZ. Samples were infected and stained as in 
Figure 25. Actin (red), bacteria (green) and cell nuclei (grey). Scale bars =10 µm. 
 
5.5 Changes in cytoplasmic membrane potential during bacterial 
adhesion.  
It has been reported that the sudden stop of flagellar rotation upon contact to a solid 
surface leads to an increase in the electrochemical potential of the cytoplasmic 
membrane (∆Ψ) due to the blocking of the proton flux through the flagellar motor  (Van 
Dellen et al., 2008). This rapid increase the concentration of protons in the periplasm 
may neutralize negative charges in the bacterial OM, thus facilitating adhesion of 
bacteria to surfaces with net negative charge (Van Dellen et al., 2008). Interestingly, 
the surface mammalian cells, and especially in the case of tumor cells, is reported to 
have a net negative charge. Some studies have also reported that a net positive 
charge of nanoparticles (Rahman et al., 2017) and bacteria (Heckels et al., 1976) 
enhance their attachment to mammalian cells.   
To evaluate the role of ∆Ψ we examined the effect of valinomycin in the bacterial 
adhesion to Her14 cells. Valinomycin is a neutral ionophore for cations, with a high 
specificity for K+, that permeates biological membranes freely dissipating ion gradients 
across the membrane and the ∆Ψ.  Valinomycin combines reversibly with K+ ions to 
form a membrane-permeable complex that diffuses across the inner membrane and 
releases K+ on the inside. This movement of charge reduces the value of ∆Ψ but does 
not affect motility of flagella. However, we found that addition of Valinomycin during the 
adhesion assay does not interfere with the attachment of the EcM1 SAegfr bacteria to 
Her14 cells. Therefore, the transient increase of ∆Ψ induced by the stop of flagellar 
motors upon contact with a surface is not required the adhesion of engineered bacteria 
to tumor cells. 





Figure 42. Inhibiting the electrochemical membrane potential does not inhibit bacterial adhesion 
to target tumor cells. Confocal fluorescence microscopy images of Her14 cells infected with 
EcM1SAegfr bacteria incubated with Valinomycin  at the indicated concentrations (0, 5 and 10 
µM). Samples were stained to visualize actin (red) and cell nuclei (grey). Bacteria (green) 
express GFP in their cytoplasm. Scale bars=10 µm. 
 
Albeit our previous data recognized the importance of flagellar rotation for 
adhesion, we did not have a satisfactory model that could explain how flagella act 
during the attachment of bacteria to cells. To gain some insight into this issue, we 
performed detailed live video microscopy with the idea to observe the adhesion 
process in real-time. (See videos V7 and V8). In the vas majority of cases we observed 
that motile bacteria reach the surface of the mammalian cell and "scan" briefly the cell 
surface before establising or not a permanent adhesion. These initial contacts are 
mediated by one pole of the bacterium, opposite to the direction of flagellar filaments 
and bacterial movement (See Figure 43A and video 7). The bacterium may stay in this 
"transient" adhesion stage for ca. 1 min, twisting around this intial contact point. If no 
additional contacts with the cell surface are established during this stage, the 
bacterium eventually leaves swimming in a different direction and then permanent 
adhesion does not occur. In contrast, if the bacterium is able to find an additional 
anchor point in the cell membrane, and thus more than one adhesion contacts are 
established simultaneously, the initial transient adhesion transforms into a a permanent 
attachment of the bacterium (Figure 43B and video 8). In these cases, the bacterium 
rod is parallelel to the cell surface and contacts are established along the bacterial 
body and not in only at the bacterial pole. Eventually, bacterium with a lateral contact to 
the cell stops any visible movement, suggesting that the flagellar motors have stopped. 
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Therefore, these data indicate that a motile flagella is needed for the bacterial twisting 
after the initial contact in order to establish additional contacts that transform the 
transient contact into a permanent attachment.  
Figure 43. Live microscopy images of the bacterial adhesion process.  Bright field microscopy 
images of six time points (within 2 min) showing a representative example of a bacterium 
(pointed with an arrow) contacting a cell with the bacterial pole and (A) not producing a 
permanent adhesion or (B) leading to a permanent adhesion establishing multiple contacts with 
the bacterial body. Her14 cells were infected with EcM1SAegfr bacteria at a MOI 30:1.  
 
5,6 Requirement of flagella for bacterial cell attachment mediated 
by natural adhesins 
At this stage, it was interesting to investigate if the dependence on the flagellar 
motility also happens with natural adhesins expressed by pathogenic bacteria for host 
cell attachment, and not only in the engineered E. coli strains with synthetic adhesins. 
Interestingly, it has been reported that the absence of flagella in certain pathogens 
reduces significantly their virulence (Chaban et al., 2015). To investigate the role of 
flagella for cell attachment mediated by pathogens, we expressed in E. coli different 
adhesins from pathogenic strains and performed adhesion assays to mammalian cells 
grown in culture.  
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We first expressed invasin form Yersinia pseudotuberculosis given its structural 
similarity to synthetic adhesins (Oberhettinger et al., 2012). Invasin is an OM adhesin 
closely related with intimin from EPEC and EHEC strains. The structure is composed of 
an N-terminal signal peptide, a short periplasmic α domain, a β-barrel domain inserted 
in the OM, and a repeat of extracellular Ig-like (D1-D4) domains and a C-terminal 
lectin-like domain. Invasin binds β-integrins on the host cell surface to trigger 
internalization of the bacteria.  
We expressed invasin under the control of the PBAD promoter, using the suicide 
vector employed previously for invasin integration in yfaL (Figure 9). This construct was 
integrated in EcM1 wild type and ∆fliCD strains expressing GFP. Bacterial cultures of 
the resulting strains were induced with L-Ara and used to infect Her14 cells for 30 min. 
After washing unbound bacteria, samples were stained for fluorescence microscopy 
(Figure 44). This experiment showed that bacterial adhesion mediated by Invasin also 
requires the expression of flagella. 
 
Figure 44. Invasin-mediated cell adhesion requires expression of flagella in E. coli Confocal 
microscopy images of Her14 cells infected for 30 min with E. coli wild type and ∆fliCD strains 
expressing invasin and GFP. Strains EcM1-araCPBAD-inv and EcM1∆fliCD-araCPBAD-inv 
were grown with L-Ara and used to infect Her14 cells for 30 min (MOI 300:1). Samples were 
infected and stained as in Figure 25. Actin (red), bacteria (green) and cell nuclei (grey). Scale 
bars =10 µm. 
Next, we decided to test a natural adhesin with a completely different structure, 
namely the type I fimbriae, which are a crucial factor for the infection of uropathogenic 
E.coli (UPEC) mediating the adhesion of bacteria to manose-containing glycoproteins 
of human urothelium (Terlizzi et al., 2017).   The adhesin tip subunit of type I fimbria 
(FimH) consist of an N-terminal lectin domain with the mannose-binding site and a C-
terminal pilin domain responsible for incorporating FimH into the fimbrial structure 
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(Mydock-McGrane et al., 2017). The EcM1 strain, which has a deletion in the 
chromosomal type I fimbria operon (fimA-H), and its isogenic non-motile strain 
EcM1∆fliCD, were transformed with plasmid pSH2, encoding the entire fim operon from 
UPEC strain J96 (Hagberg et al., 1983).  In vitro adhesion assays using these bacteria 
on the human bladder cell line HTB9 showed that only motile wild type bacteria 
expressing the type I fimbria attached to human bladder cells HTB9 (Figure 45). 
 
Figure 45. Type I fimbriae-mediated adhesion of human bladder cells requires expression of 
flagella. Confocal microscopy images of HTB-9 human bladder cells infected for 30 min with 
EcM1 motile and ∆fliCD mutant bacteria (MOI 300:1) expressing GFP and carrying pSH2, 
encoding the type I fimbriae operon from UPEC J96 strain. Samples were infected and stained 
as in Figure 25. Actin (red), bacteria (green) and cell nuclei (grey). Scale bars =10 µm.  
 
The above experiments demonstrate that flagella is an essential organelle for the 
adhesion of E.coli to mammalian cells, not only with synthetic adheins but also with 
natural afimbrial and fimbrial adhesins from pathogenic bacteria, like invasin and type I 
fimbria.  
Lastly, we wanted to test whether flagella were also relevant for the adhesion of a 
non-E. coli pathogen like Salmonella enterica sv. typhimurium. It has been reported 
that the flagella is an important virulence factor for this strain, and this could be directly 
related with its ability of attach to the host cells (Barbosa et al., 2017). 
Motile S. typhi sv.typhimurium strain and its isogenic non-motile ∆flhDC strain were 
used for infection of normal rat kidney (NRK) fibroblasts (MOI 100:1). After 1 h 
infection, cells were washed and differentially stained to visualize intracellular and 
extracellular bacteria by fluorescence microscopy (Figure 46). This experiment also 
revealed that attachment of S. typhimurium to host cells also depends on the 
expression of flagella, corroborating our previous results with E. coli bacteria. 
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Figure 46. Adhesion of Salmonella enterica sv. typhimurium to NRK fibroblasts depends on the 
expression of flagella. Confocal microscopy images of NRK fibroblasts infected with S. 
typhimurium and isogenic ∆flhDC mutant bacteria (MOI 100:1) for 60 min. Extracellular bacteria 
were first stained with anti-Salmonella LPS rabbit polyclonal serum and secondary anti-rabbit-
Alexa 594 (red). Cells were then permeabilized (0.1% TX-100) and stained with anti-Salmonella 
LPS and secondary anti-rabbit-Alexa 448 (green) to label both extracellular and intracellular 
bacteria. Extracellular bacteria are stained brown (red + green). Intracelllular bacteria are 








1.  Engineered bacteria targeting human epithelial cancer cells  
Certain types of bacteria are extraordinary alternatives for treating cancer given 
their natural ability to colonize solid tumors, intratumoral penetration capability, and 
easy of genetic manipulation. However, numerous challenges remain before these 
bacteria can be used in the clinic, including intrinsic bacterial toxicity, targeting 
efficiency and genetic instability. Several strategies have been developed for modifying 
bacteria with this purpose and the most widely studied bacteria for cancer therapy is S. 
typhimurium. But Salmonella presents obvious inconveniences given that its 
pathogenic character, immunogenicity and risk of causing a septic shock.  
To reduce the immunogenicity of Salmonella, the VPN20009 strain was created by 
deleting both the purI and the msbB genes (Pawelek et al., 1997). This attenuated 
Salmonella strain has been used already in Phase I clinical trials involving patients with 
advanced or metastatic cancer where 3x108CFU/m2 was defined as the maximum 
tolerated dose in 25 patients treated intravenously with the bacteria. Colonization of the 
tumor was observed in just three of patients and no tumor regression was observed 
(Cunningham and Nemunaitis, 2001). Some clinical toxicity was also reported like 
hypotension, fever, anemia, diarrhea, nausea, and vomiting, probably due to the high 
dose of bacteria (Cunningham and Nemunaitis, 2001). The reduction of the bacterial 
dose for tumor colonization and the use of a less immunogenic bacterial strain could 
definitely present an essential alternative for developing an anti-cancer therapy using 
bacteria.  
Previously in our laboratory, a non-pathogenic E. coli K-12 strain lacking the Type 1 
fimbriae, Antigen 43 and Mat fimbriae, were modified to express a SA targeting GFP 
antigen expressed on the surface of HeLa tumor cells. This experimental model 
allowed a significant reduction (two orders of magnitude) of the bacterial dose needed 
for optimal tumor colonization in vivo. In addition, it was found out that the engineered 
E.coli strain is retained at lower levels than the wild type strain in non targeted organs 
such as liver and spleen probably caused by the lack of some adhesins naturally 
expressed by E. coli (Pinero-Lambea et al., 2015a). 
Based on this work, we aimed to develop SAs recognizing actual surface antigens 
expressed on human tumor cells and target engineered E. coli bacteria against these 
molecules.  
	 94	
In this work, we have characterized the affinity of Nbs binding human EGFR 
(Salema et al., 2016) whose expression is altered in many epithelial carcinomas and 
which is the target of many approved anti-cancer drugs (Tebbutt et al., 2013). We 
employed these Nbs to build high-affinity SAs that allow E. coli to attach to human 
bladder and colon tumor cell lines expressing EGFR. Albeit our engineered bacteria 
attach with good efficiency to all EGFR-expressing cell lines tested, the adhesion levels 
were higher in colon cancer cell lines (e.g. HCT116, DLD2) than in bladder cell lines 
(e.g. T24, UMUC3). This result was surprising because EGFR expression levels is 
similar in all these cell lines according to flow cytometry analysis, and thus this 
difference could be due a reduced accesibilty of this receptor or a mechanism of 
inhibition of bacterial attachment by some undefined property of the surface of bladder 
cells. Despite  these differences, bacterial attachment was sufficiently high and specific 
in both bladder and colon carcinoma cells to open the possibility of targeting these 
tumors using bacterial administration routes (e.g. intravesical, oral) that are safer than 
systemic administration into the blood stream. In comparision with the currently 
approved anti-EGFR antibodies (e.g. Cetuximab, Panitumumab) (Martinelli et al., 
2009), whose action is confined to the irrigated areas of the tumor, bacteria expressing 
anti-EGFR SAs have the potential to be used at safer doses and actively penetrate into 
the core of the tumor to spread the therapeutic effect.  
 
17. 2. Engineering invasive bacteria of target tumor cells for release 
of protein payloads. 
The principal aim of bacterial cancer therapies is to perform an action in the tumor 
area for tumor cell killing (Forbes, 2010). For this purpose, the bacteria need to be able 
to deliver the desired molecule in the tumor area, ideally specifically in the tumor cell, 
to avoid toxicity effectos in healthy tissues. The invasion and subsequent release of a 
therapeutic protein payload inside the target tumor cell was an interesting alternative 
that we have investigated in combination with SAs. Our results demonstrate that 
combining the constitutive expression of SAs binding EGFR with the subsequent 
inducible expression of invasin allow massive internalization of EGFR-positive tumor 
cells by the engineered bacteria. Leaky expression of invasin from PBAD promoter in 
media lacking glucose is suffient to observe internalization of individual bacteria, 
although induction with L-ara triggers a massive internalization of bacterial clusters. 
Intracellular bacterial pathogens possess several mechanisms of invading the host 
cells including a fast escape from the phagosome and the modification of the vacuole 
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bacteria contents to avoid death via phagosomal acidification (Pizarro-Cerda and 
Cossart, 2006). The E. coli K-12 strain does not have any of these complex 
mechanisms and for the delivery of therapeutical molecules inside target cells, we 
needed to include the expression of different genetic modules. An alternative that has 
been previously used for the delivery of several types of molecules inside mammalian 
cells is the expression in E. coli of invasin from Yersinia pseudotuberculosis on the 
bacterial surface in combination with the pore-forming LLO protein from Listeria 
monocytogenes (Higgins et al., 1999). This strategy was repoerted to trigger 
internalization of the bacterium and the release of bacterial content into the cell 
cytoplasm.  For instance, antigens like ovoalbumin (OVA) have been released in 
dendritic cell cytoplasm using E. coli expressing cytoplasmic LLO. Dendritic cells or 
macrophages are professional phagocytic cells and are highly specialized in the 
engulfment and lysis of invading bacteria. Therefore, bacteria enter these phagocytic 
cells without the need of invasin. The phagocytic cell is then able to lyse the bacteria 
liberating their content inside the phagosome. The LLO in the bacterial cytoplasm is 
released and forms pores in the membrane of the phagosome, delivering the bacterial 
content into the host cell cytoplasm (Higgins et al., 1999; Radford et al., 2002).   
An engineered auxotrophic for diaminopimelic acid (dap) and invasive E. coli was 
reported to as being able to mediate gene transfer into epithelial cells transferring 
plasmid DNA vectors (Fajac et al., 2004). However, the gene transfer efficiency was 
low and took at least three hours for bacteria to reach the phagosome compartment. In 
the case of the DNA vectors, trafficking into the nucleus of the target cell should take 
place (Castagliuolo et al., 2005; Fajac et al., 2004). An invasive E. coli encoding 
shRNA against CTNNB1 (catenin b-1) was reported to induce gene silencing in the 
intestinal epithelium and in human colon cancer xenografts in mice (Xiang et al., 2006). 
These results indicated that invasive E. coli is able to release nucleic acids into the 
cytoplasm of non-phagocytic cells. However, these studies did not report the release of 
a protein paylod.  To investigate this possibility we used a dap auxotroph and invasive 
E.coli expressing LLO to release a reporter protein enzyme (ß-lactamase) into HCT116 
colon epithelial tumor cells. The E. coli strain expressed LLO into the bacterial cytosol 
or in the periplasm of the bacterium to facilitate a faster release of the protein in the 
phagosome.  Despite massive bacterial invasion, only a weak liberation of ß-lactamase 
into the cytoplasm of the tumor cells was detected after 24 h of infection with the dap 
auxotroph strain expressing the LLO in the cytosol.  This results suggest that some 
intracellular protein release is possible under in vitro conditions (cell culture), but the 
system might not be efficient in vivo. As a control, we included the SIEC strain (E.coli 
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K-12 expressing the type III secretion system from EPEC) (Ruano-Gallego et al., 2015) 
that is able to inject ß-lactamase directly to the target cell cytoplasm. This control 
shows a much higher efficiency of protein injection into the cytosol, especially at short 
times after bacterial adhesion. Bacterial T3SS are highly versatible systems allowing 
translocation of different effectors to heterologous proteins into the cytosol of 
mammalian cells (REFS) (Galan et al., 2014; Portaliou et al., 2016). Nonetheless, 
constrains in the pore diameter of T3SS and limitations in the unfolding capacity of the 
proteins to be translocated restrict the actual number of proteins able to be injected by 
these molecular nanosyringes (Barison et al., 2013; Lee and Rietsch, 2015). it is knwon 
that effector proteins of T3SS unfold in the cytosol in order to pass through the 
cytosolic entrance of the injectisome (Akeda and Galan, 2005). Strongly folded proteins 
are not translocated through injectisomes (Dohlich et al., 2014), (Notti and Stebbins, 
2016). To be able to deliver a wider spectrum of molecules having these limitations, an 
improvement of protein delivery  trough cell invasion might be necessary. A critical step 
in the whole process is the inability of rapid release of the bacterial content from the 
phagosome of non-phagocytic cells. 
An interesting alternative for a faster liberation of cargo molecules after 
internalization could be the combination of the two delivery strategies develop in our 
laboratory, using the T3SS injectisomes to facilitate the escape of bacterial content 
from the phagosome. Interestingly, it has been reported the efficient escape of invasive 
E. coli bacteria from phagosomes after internalization thanks to the pore formation in 
the phagosome membrane by T3SS (Du et al., 2016).  Although not all T3SS are able 
to reproduce this phenotype, (the type III secretion system from Yersinia does not 
produce the liberation of the bacteria (Du et al., 2016)), it would be interesting to test 
whether the EPEC T3SS in SIEC  is able to produce the liberation of the E. coli from 
the phagosome in combination with the invasin protein.  
18.  
19. 3. Minicells with synthetic adhesins as nanoparticles for protein 
delivery in tumor cells.  
Systemic administration of chemotherapeutic drugs causes a severe toxicity in 
healthy tissues. A deeply studied approach to reduce the toxicity of these therapeutical 
molecules is their encapsulation in nanovehicles to deliver the drug only in the tumor 
area. In this regard, liposomes and other nanoparticles are able to accumulate in the 
tumor area thanks to the leaky vasculature resulting from the deregulated nature of the 
tumor angiogenesis (Miao and Huang, 2015). Once inside the tumor, these 
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nanoparticles break down and release a high concentration of the drug, reducing the 
general toxicity but still with side effects such as skin toxicity (including hand-foot 
syndrome and mucositis).  
Nanoparticles can be targeted to specifically recognize tumoral cells and thereby 
achiving higher concentrations of the drug in the tumor area and making the therapy 
safer.  Nanoparticles targeting cell surface receptors overexpressed in tumor cells such 
as EGFR or Her2 have being developed (Flemming, 2007).  
An improvement in drug encapsulation will be to generate a nanoparticle that is 
easier to produce, able to contain a wide spectrum of molecules, possesses the 
sufficient integrity to not leak the therapeutic molecule until confined to the tumor area 
and recognizing specifically the tumor cells and not the healthy tissues. Minicells 
(bacteria derived nanoparticles) present an extraordinary option as nanovehicles and 
has been used already in antitumoral treatments for systemic administration of a wide 
spectrum of molecules including chemotherapeutics, siRNA, or bacterial toxins against 
tumoral cells (MacDiarmid and Brahmbhatt, 2011). Minicells are able to carry a 
concentration from one to ten millions of molecules in comparison with liposomes that 
can carry only up to 10.000 molecules. The targeting of minicells with bispecific 
antibodies recognizing the minicell surface and specific molecules on tumor cell 
surface, improved the tumor targeting in a considerable way (MacDiarmid et al., 2007). 
Minicell production protocol consists in different step from minicells purification, 
minicells loading with the therapeutic molecule and several steps of incubation with 
antibodies if we want to create target minicells.  Interesntly, a recent study have 
reported the therapeutic effect of VAX-IP - an E. coli-derived minicells lacking dapA 
(DAP auxotrophy) and lpxM (less immunogenic lipid A) genes (for biosafety reasons) 
and containing perfringolysin as an antitumor toxin (Tsuji et al., 2016).  The 
internalization of these minicells was achieved with invasin on the bacterial surface for 
the treatment of xenograft bladder tumors in mice. In vitro infection with VAX-IP results 
in the internalization on minicells mediated by invasin.  
 
In this PhD thesis we reduced the process for generation of minicells to just one 
step by creating minicells already loaded with a protein of interest and expressing a 
SAs against EGFR on their surface. However, minicells expressing the SA against 
EGFR presented a weak adhesion to tumor cells expressing EGFR in vitro despite the 
fast and robust adhesion to live bacteria with the same SA to these cells.  When 
minicells have been reported to be used in vivo, a high dose of minicells (5x108/animal) 
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needs to be administered in multiple inoculations in order to see a significant anti-tumor 
effect, both in subcutaneous and orthotopic tumor models  (MacDiarmid and 
Brahmbhatt, 2011; Tsuji et al., 2016) These data also suggest a poor targeting of 
minicells to tumor cells in these studies. The number of live bacteria needed for 
colonization of solid tumors (ca. 106-107 in the absence of SA) is much lower than the 
number of minicells administered in vivo with a targeting mAb or invasin. Hence, live 
bacteria appear to be more appropiate vehicles for tumor targeting with SAs. In 
addition of their simple and inexpensive production, live bacteria are able to survive 
and replicate inside the tumor, keeping continuous expression of antitumor molecules.  
In our study we have determined that a major factor explaining the poor adhesion of 
minicells to tumor cells in comparison with bacteria (expressing the same SA) is the 
lack of motility in non-live minicells.  
 
20. 4. Importance of flagella for bacterial adhesion 
Bacteria need to get in close proximity to initiate attachment to any surface (Berne 
et al., 2018). Our results have determined that, in addition to this initial contact, 
bacteria need to establish multiple adhesion sites to become permanently attach to the 
surface of a mammalian cell. Flagella power the swimming motility that enables the 
bacteria to approach a solid surface. In addition, flagella are also involved in signal 
transduction in response to chemical and mechanical inputs, can trigger bacteria cell 
differentiation and participate in important steps during host infection (Berne et al., 
2018).  
In this PhD thesis, it has been demonstrated that an active flagellar motility, and not 
the presence of an inactive flagellar filament, is required for the efficient and permanent 
adhesion of bacteria to tumor cells. E. coli motA mutants assemble flagella but are 
unable to attach to cells. Flagellar motility facilitates the initial contact of the bacterium 
with the cell, which mostly occurs with the bacterial pole, due to bacterial swiming. This 
is the reason why bacterial "tumble" mutants (ΔcheZ) have a reduced adhesion to cells 
unless the initial contact is facilitated by a different mechanism (e.g. centrifugation). 
Importantly, flagellar motility is also needed for the transition to a permanent 
attachment. We have shown that bacterium needs to adopt a parallel position to the 
cell surface after the initial contact with the bacterial pole, establishing different binding 
spots in the main rod body of the bacterium, allowing to remain permanently attached 
to the mammalian cell even under strong shear forces in fast flow conditions.  
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From these results we can conclude that the flagella is helping the bacterium to 
make initial contact with the cell and, subsequently, is twisting the bacterial body which 
then "traps" the bacterium establising several adhesion spots. The mechanism may 
find a parallelism in the way insects become trapped in spider webs, since movement 
of the bug make it become attach in further spots by the web. In addition, we found that 
this is happening not just in the case of the adhesion through synthetic adhesins, but 
also with natural adhesins from pathogenic bacteria like invasin for Yersinia 
pseudotuberculosis and type I fimbiae from uropathogenic E. coli. We also found that a 
∆flhDC mutant of Salmonella is not able to invade NRK-fibroblast cells. Hence, our 
results have implications to understand adhesion of host cells by pathogenic strains 
and not only for the use of bacteria against cancer. It has been described that the 
flagellum is an important pathogenicity determinant in numerous pathogens such 
E.coli, Listeria, Salmonella and Caulobacter, in which their ultimate goal is to invade or 
attach to the host cell (Chaban et al., 2015) (Berne et al., 2018). 
In addition, overexpression of the master flagellar regulator flhDC, which iincrease 
the number of flagella in the bacterial body, has been found to increase invasion of 
Salmonella to tumor masses in vitro and colonization of tumors in vivo (Raman et al., 
2019) (Thornlow et al., 2015; Toley and Forbes, 2012).  
Flagella are described to be key elements from a transient to a permanent bacterial 
attachment in biofilms (Van Dellen et al., 2008). The proton motive force (∆Ψ) has been 
suggested to play a role in this process. When bacteria are swimming in liquid media 
the ∆Ψ is maintained at a constant level. When the cell attached to a surface, the 
flagellar motors cannot rotate and it stops the flow of ions through the motor, resulting 
in a transient increase of ∆Ψ (Van Dellen et al., 2008). This may indicate to the 
bacterium that is close to a surface and initiates the transition to a permanent 
attachment. For instance, Vibrio cholera monolayer formation in abiotic surfaces is 
inhibited by addition of valinomycin, an antibiotic which suppress the ∆Ψ (Van Dellen et 
al., 2008). However, we found that addition of valinomycin does not inhibit the 
adhesion of E. coli to tumor cells.  
It is interesting understanding the molecular pathways implicated in flagellar signal 
transduction. Currents studies indicate that the second messenger cyclic di-GMP (ci-di-
GMP) inhibits motility in bacteria (Paul et al., 2010). This dinucleotide is produced by a 
family of enzymes called diguanylate cyclases (DGCs) and is able to inhibit bacterial 
motility directly by interaction with the YcgR brake protein in E. coli (Boehm et al., 
2010). The transcription of the major DGC in E. coli, DgcZ, is activated by the 
lipoprotein NlpE in response to surface sensing (Lacanna et al., 2016). YcgR bound to 
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c-di-GMP is able to stop flagella by interaction with FliM and FliG component of flagella 
rotor (Paul et al., 2010). In our work we found that overexpression of c-di-GMP in the 
E. coli WT strain, but not and in the ∆ycgR mutant, stopped flagellar motility. However 
the absence of this brake protein did not have any apparent effect in the adhesion 
process to tumor cells. E. coli ∆ycgR strain expressing the SA against EGFR was able 
to reach and bind tumor cells expressing EGFR on their surface at normal levels and 
remained permanently attached to the cell. 
In conclusions, our observations clearly support the essential role of active flagellar 
motility in bacterial adhesion to mammalian cells, and highlight the importance of this 
process for adhesion to tumor cells by synthetic bacteria and also during host cell 
adhesion and invasion by bacterial pathogens. Our findings also indicate that is not 
necessary a fast stop of the flagella mediated elevated c-di-GMP levels induced by 
known surface sensors (i.e.NlpE, DgcZ, YcgR), or and increase in ∆Ψ, for the bacteria 






1. The affinity and binding competition of five different nanobodies binding human 
EGFR has been chracterized. Two nanobody clones showing high affinity and 
binding to different epitopes on the EGFR molecule have been selected for 
construction of E. coli synthetic adhesins.  
 
2. We have demonstrated the constitutive and stable expression of synthetic 
adhesins against EGFR on E. coli surface after insertion of genetic constucts in 
the bacterial chromosome. This expression drives the specific adhesion the 
modified bacterium to human epithelial tumor cell lines expressing EGFR, 
including bladder and colon carcinomas. 
 
3. We have engineered the inducible expression of invasin from Yersinia 
pseudotuberculosis in the chromosome of E. coli bacteria expressing synthetic 
adhesins against EGFR. Induction of invasin upon bacterial adhesion leads to 
the specific invasion of tumor cells. Bacterial invasion increase apoptosis of 
tumor cells but it is not sufficient to cause a massive death of the infected tumor 
cells. 
 
4. We have found that a bacterial protein cargo can be detected in the cytoplasm 
of the invaded tumor cells after 24 h of infection, especially when the 
engineered bacterium carries an auxotrophy for diaminopimelic acid (inducing 
its lysis in the endosome) and co-expresses LLO from Listeria monocytogenes.  
 
 
5. We have produced non-live E. coli minicells expressing synthetic adhesins 
against human EGFR on their surface and a cargo protein in their cytosol. The 
adhesion to tumor cells achieved in vitro by these engineered minicells was 
poor in comparison with live bacteria, despite higher titers and longer incubation 
times used with minicells. 
 
6. We have found that bacterial motility mediated by flagella is required for the 
efficient adhesion of E. coli bacteria expressing synthetic adhesins to target 
tumor cells. E. coli mutants lacking flagella or having a non-motile flagella are 
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not able to bind to target tumor cells despite the expression of the synthetic 
adhesins. This adhesion defect of non-motile bacteria is not compensated by 
bacterial movement in an unidirectional flow or by centrifugation to force cell 
contact.  
 
7. At least one of the flagellar rotation movements, CCW or CW, leading to linear 
swimming or tumbling motility of the bacterium, is required to trigger the 
permanent adhesion of bacteria with synthetic adhesins upon an initial cell 
contact. Tumbling mutants need to force this initial cell contact (e.g. by 
centrifugation) due to their lack of a linear swimming. 
 
8. Real-time live microscopy indicate that an individual E. coli bacterium must 
establish simultaneously several adhesion points to the plasma membrane of 
the tumor cell in order to produce a permanent adhesion event.  After an initial 
cell-contact, the flagellar activity is needed for the generation of local bacterial 
movements that allow the establishment of additional adhesion points between 
the bacterium and the tumor cell. We do not observe movement of bacteria 
attached to cells, suggesting the stop of the flagellar motor after a permanent 
attachment is established.     
 
9. Neither the absence of the flagellar "brake" protein YcgR, nor of NlpE and DcgZ 
components of the c-di-GMP-signalling pathway activating YcgR, have any 
significant effect on the adhesion of bacteria to tumor cells. In addition, the 
adhesion process in not affected by the dissipation of the electrochemical 
potential of the bacterial plasma membrane mediated by Valinomycin.  
 
10. We found evidence that the dependence of the flagella for bacterial adhesion 
also occurs in the case of natural adhesins expressed in E. coli (i.e. invasin and 
type I fimbriae) and for the adhesion and invasion of mammalian cells by 





1. Hemos caracterizado la afinidad y competición de cinco anticuerpos 
monodominio que unen el EGFR humano. Seleccionamos dos "nanobodies" 
con alta afinidad y reconocimiento de epítopos distintos dentro de EGFR para 
constuir adhesinas sintéticas de E. coli. 
2. Hemos demostrado la expresión constitutiva y estable de las adhesinas 
sintéticas frente EGFR en la superficie de E.coli tras la inserción de los 
constructos genéticos en el cromosoma bacteriano. La expresión de las 
adhesinas permitió dirigir la adhesión específica de las bacterias modificadas a 
células tumorales que expresan EGFR, incluyendo carcinomas de vejiga y 
colon.  
3. Hemos generado la expresión inducible de invasina de Yersinia 
pseudotuberculosis en el cromosoma de bacterias E. coli que expresaban las 
adhesina sintéticas frente a EGFR. La inducción de la invasina tras la adhesión 
bacteriana permite una invasión específica de las células tumorales. La 
invasión bacteriana incrementa la apoptosis de las celulas tumorales pero es 
insuficiente para causar una muerte masiva de las células tumorales 
infectadas.  
4. Hemos comprobado que una proteína "cargo" expresada en la bacteria puede 
ser detectada en el citoplasma de la célula tumoral invadida 24 horas tras la 
infección, especialmente cuando la bacteria es auxótrofa para diaminopimélico 
(lo que induce su lisis en el endosoma) y coexpresa LLO de Listeria 
monocytogenes.  
5. Hemos producido minicélulas no vivas de E. coli que expresan SAs frente a 
EGFR en su superficie y una proteína "cargo" en el citosol. La adhesión a 
células tumorales lograda in vitro por estas minicélulas modificadas fue muy 
escasa en comparación con las bacterias vivas, incluso utilizando altas dosis 
de minicélulas y largos tiempos de incubación.  
6. La motilidad bacteriana mediada por el flagelo es requerida para una adhesión 
efectiva de la bacterias E. coli que expresan SA contra EGFR. Los mutantes de 
E. coli que no tienen flagelo, o poseen un flagelo no motil, no son capaces de 
unirse a las células tumorales diana. Este defecto en la adhesión no puede ser 
compensado con el movimiento de la bacteria en un flujo unidireccional o 
mediante centrifugación para forzar el contacto entre la bacteria y la célula.  
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7. Al menos uno de los movimientos de rotación flagelar, CCW o CW, que dirigen 
una natación lineal o rotatoria, es sufiente para que la bacteria pase de una 
adhesión transitoria a una permanente una vez ha contactado con la célula 
diana. Los mutantes que nadan en movimiento rotatorio necesitan una fuerza 
inicial que dirija a la bacteria contra la célula (ej. centrifugación) debido a la falta 
de dirección en el movimiento.  
8. La microscopía a tiempo real con células vivas indica que una bacteria E. coli 
debe establecer simultáneamente varios puntos de adhesion a la membrana de 
la célula tumoral para que se produzca una adhesión permanente. Tras el 
primer contacto bacteria-célula tumoral, la actividad del flagelo es necesaria 
para la generación de movimientos locales de la bacteria que permiten el 
establecimiento de puntos de adhesión adicionales. Tras esta adhesión 
permanente no se observa movimiento de la bacteria, lo que sugiere una 
parada de la rotación del flagelo.  
9. La falta de proteína “freno” del flagelo YcgR, o de las proteínas de la ruta de 
señalización de c-di-GMP que activa YcgR, no son necesarias para la  
adhesión de la bacteria a la célula. El proceso de adhesión tampoco se ve 
afectado por la disipación de potencial de membrana debido a la adición del 
antibiótico Valinomicina.  
10. Hemos comprobado que la dependencia del flagelo para la adhesion 
bacteriana también ocurre en el caso adhesinas naturales expresadas en E. 
coli como la invasina de Yersinia pseudotuberculosis o las fimbrias tipo I de E. 
coli uropatógenas, así como para la adhesión e invasión de células de 
mamífero por Salmonella enterica sv. typhimurium.  
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